{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:19:16Z","timestamp":1783574356012,"version":"3.55.0"},"reference-count":363,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["No. 2025CX34"],"award-info":[{"award-number":["No. 2025CX34"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82274024"],"award-info":[{"award-number":["No. 82274024"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04518-8","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:12:32Z","timestamp":1778512352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gene therapy for liver diseases: methods, challenges and opportunities"],"prefix":"10.1186","volume":"24","author":[{"given":"Mengyao","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"4518_CR1","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1016\/j.ymthe.2023.11.001","volume":"31","author":"D Chancellor","year":"2023","unstructured":"Chancellor D, Barrett D, Nguyen-Jatkoe L, Millington S, Eckhardt F. The state of cell and gene therapy in 2023. Mol Ther. 2023;31:3376\u201388.","journal-title":"Mol Ther"},{"key":"4518_CR2","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.ymthe.2025.04.004","volume":"33","author":"GL Butterfield","year":"2025","unstructured":"Butterfield GL, Reisman SJ, Iglesias N, Gersbach CA. Gene regulation technologies for gene and cell therapy. Mol Ther. 2025;33:2104\u201322.","journal-title":"Mol Ther"},{"key":"4518_CR3","doi-asserted-by":"publisher","first-page":"100975","DOI":"10.1016\/j.preteyeres.2021.100975","volume":"86","author":"C Botto","year":"2022","unstructured":"Botto C, Rucli M, Tekinsoy MD, Pulman J, Sahel JA, Dalkara D. Early and late stage gene therapy interventions for inherited retinal degenerations. Prog Retin Eye Res. 2022;86:100975.","journal-title":"Prog Retin Eye Res"},{"key":"4518_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6:53.","journal-title":"Signal Transduct Target Ther"},{"key":"4518_CR5","first-page":"5997","volume":"29","author":"M Laurent","year":"2024","unstructured":"Laurent M, Geoffroy M, Pavani G, Guiraud S. CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments. Cells. 2024;29:5997.","journal-title":"Cells"},{"key":"4518_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ymgme.2008.12.016","volume":"96","author":"JM Wilson","year":"2009","unstructured":"Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab. 2009;96:151\u20137.","journal-title":"Mol Genet Metab"},{"key":"4518_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.ymthe.2020.02.010","volume":"28","author":"AH Baker","year":"2020","unstructured":"Baker AH, Herzog RW. Did Dendritic Cell Activation, Induced by Adenovirus-Antibody Complexes, Play a Role in the Death of Jesse Gelsinger? Mol Ther. 2020;28:704\u20136.","journal-title":"Mol Ther"},{"key":"4518_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.stem.2023.04.014","volume":"30","author":"S Ferrari","year":"2023","unstructured":"Ferrari S, Valeri E, Conti A, Scala S, Aprile A, Di Micco R, Kajaste-Rudnitski A, Montini E, Ferrari G, Aiuti A, Naldini L. Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy. Cell Stem Cell. 2023;30:549\u201370.","journal-title":"Cell Stem Cell"},{"key":"4518_CR9","doi-asserted-by":"publisher","first-page":"102184","DOI":"10.1016\/j.omtn.2024.102184","volume":"35","author":"S Li","year":"2024","unstructured":"Li S, Xiong F, Zhang S, Liu J, Gao G, Xie J, Wang Y. Oligonucleotide therapies for nonalcoholic steatohepatitis. Mol Ther Nucleic Acids. 2024;35:102184.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4518_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41587-023-02105-y","volume":"42","author":"V Jadhav","year":"2024","unstructured":"Jadhav V, Vaishnaw A, Fitzgerald K, Maier MA. RNA interference in the era of nucleic acid therapeutics. Nat Biotechnol. 2024;42:394\u2013405.","journal-title":"Nat Biotechnol"},{"key":"4518_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1056\/NEJMoa2410597","volume":"392","author":"A Srivastava","year":"2025","unstructured":"Srivastava A, Abraham A, Aboobacker F, Singh G, Geevar T, Kulkarni U, Selvarajan S, Korula A, Dave RG, Shankar M, et al. Lentiviral Gene Therapy with CD34\u2009+\u2009Hematopoietic Cells for Hemophilia A. N Engl J Med. 2025;392:450\u20137.","journal-title":"N Engl J Med"},{"key":"4518_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/jimd.12637","volume":"47","author":"MA Chuecos","year":"2024","unstructured":"Chuecos MA, Lagor WR. Liver directed adeno-associated viral vectors to treat metabolic disease. J Inherit Metab Dis. 2024;47:22\u201340.","journal-title":"J Inherit Metab Dis"},{"key":"4518_CR13","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1038\/d41586-018-07639-9","volume":"564","author":"H Brody","year":"2018","unstructured":"Brody H. Gene therapy. Nature. 2018;564:S5.","journal-title":"Nature"},{"key":"4518_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","volume":"23","author":"D Bitounis","year":"2024","unstructured":"Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat Rev Drug Discov. 2024;23:281\u2013300.","journal-title":"Nat Rev Drug Discov"},{"key":"4518_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jconrel.2024.10.044","volume":"376","author":"Q Lai","year":"2024","unstructured":"Lai Q, Li W, Hu D, Huang Z, Wu M, Feng S, Wan Y. Hepatic stellate cell-targeted chemo-gene therapy for liver fibrosis using fluorinated peptide-lipid hybrid nanoparticles. J Control Release. 2024;376:601\u201317.","journal-title":"J Control Release"},{"key":"4518_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00204-016-1694-y","volume":"91","author":"JA Heslop","year":"2017","unstructured":"Heslop JA, Rowe C, Walsh J, Sison-Young R, Jenkins R, Kamalian L, Kia R, Hay D, Jones RP, Malik HZ, et al. Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile. Arch Toxicol. 2017;91:439\u201352.","journal-title":"Arch Toxicol"},{"key":"4518_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13287-024-03911-0","volume":"15","author":"H Xie","year":"2024","unstructured":"Xie H, Li G, Fu Y, Jiang N, Yi S, Kong X, Shi J, Yin S, Peng J, Jiang Y, et al. A two-step strategy to expand primary human hepatocytes in vitro with efficient metabolic and regenerative capacities. Stem Cell Res Ther. 2024;15:281.","journal-title":"Stem Cell Res Ther"},{"key":"4518_CR18","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3390\/cells11111843","volume":"11","author":"P Germino-Watnick","year":"2022","unstructured":"Germino-Watnick P, Hinds M, Le A, Chu R, Liu X, Uchida N. Hematopoietic Stem Cell Gene-Addition\/Editing Therapy in Sickle Cell Disease. Cells. 2022;11:1843.","journal-title":"Cells"},{"key":"4518_CR19","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1136\/gutjnl-2023-331742","volume":"74","author":"A Fontanellas","year":"2025","unstructured":"Fontanellas A, Berraondo P, Urigo F, Jerico D, Martini PGV, Pastor F, Avila MA. RNA-based therapies in liver metabolic diseases. Gut. 2025;74:1514\u201327.","journal-title":"Gut"},{"key":"4518_CR20","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1378\/chest.122.5.1818","volume":"122","author":"FJ de Serres","year":"2002","unstructured":"de Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest. 2002;122:1818\u201329.","journal-title":"Chest"},{"key":"4518_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/1753465812457113","volume":"6","author":"FJ de Serres","year":"2012","unstructured":"de Serres FJ, Blanco I. Prevalence of alpha1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis. 2012;6:277\u201395.","journal-title":"Ther Adv Respir Dis"},{"key":"4518_CR22","doi-asserted-by":"publisher","first-page":"e001281","DOI":"10.1136\/bmjresp-2022-001281","volume":"9","author":"J Acquavella","year":"2022","unstructured":"Acquavella J, Vago E, Sorensen HT, Horvath-Puho E, Hess GP. Registry-based cohort study of alpha-1 antitrypsin deficiency prevalence, incidence and mortality in Denmark 2000\u20132018. BMJ Open Respir Res. 2022;9:e001281.","journal-title":"BMJ Open Respir Res"},{"key":"4518_CR23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/joim.20058","volume":"297","author":"S Wahlin","year":"2025","unstructured":"Wahlin S, Widman L, Hagstrom H. Epidemiology and outcomes of alpha-1 antitrypsin deficiency in Sweden 2002\u20132020: A population-based cohort study of 2286 individuals. J Intern Med. 2025;297:300\u201311.","journal-title":"J Intern Med"},{"key":"4518_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1038\/gim.2014.128","volume":"16","author":"PS Kishnani","year":"2014","unstructured":"Kishnani PS, Austin SL, Abdenur JE, Arn P, Bali DS, Boney A, Chung WK, Dagli AI, Dale D, Koeberl D, et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med. 2014;16:e1.","journal-title":"Genet Med"},{"key":"4518_CR25","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.3748\/wjg.v13.i18.2541","volume":"13","author":"H Ozen","year":"2007","unstructured":"Ozen H. Glycogen storage diseases: new perspectives. World J Gastroenterol. 2007;13:2541\u201353.","journal-title":"World J Gastroenterol"},{"key":"4518_CR26","doi-asserted-by":"publisher","first-page":"23271","DOI":"10.1038\/s41598-025-06630-5","volume":"15","author":"DE Im","year":"2025","unstructured":"Im DE, Kang HY. Epidemiologic features and economic burden of Wilson\u2019s disease in South Korea: a nationwide analysis of the entire patient population. Sci Rep. 2025;15:23271.","journal-title":"Sci Rep"},{"key":"4518_CR27","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.3346\/jkms.2024.39.e115","volume":"39","author":"ES Jang","year":"2024","unstructured":"Jang ES, Choi HY, Ki M, Kim BH, Kim KA, Jeong SH. Prevalence, Incidence, and Treatment Pattern of Wilson\u2019s Disease Using National Health Insurance Data From 2010\u20132020, Korea. J Korean Med Sci. 2024;39:e115.","journal-title":"J Korean Med Sci"},{"key":"4518_CR28","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/jimd.12100","volume":"42","author":"J Haberle","year":"2019","unstructured":"Haberle J, Burlina A, Chakrapani A, Dixon M, Karall D, Lindner M, Mandel H, Martinelli D, Pintos-Morell G, Santer R, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inherit Metab Dis. 2019;42:1192\u2013230.","journal-title":"J Inherit Metab Dis"},{"key":"4518_CR29","doi-asserted-by":"crossref","unstructured":"Summar M, Tuchman M. Proceedings of a consensus conference for the management of patients with urea cycle disorders. J Pediatr 2001, 138:S6-10.","DOI":"10.1067\/mpd.2001.111831"},{"key":"4518_CR30","first-page":"302","volume":"47","author":"M De Braekeleer","year":"1990","unstructured":"De Braekeleer M, Larochelle J. Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean. Am J Hum Genet. 1990;47:302\u20137.","journal-title":"Am J Hum Genet"},{"key":"4518_CR31","doi-asserted-by":"crossref","unstructured":"Sambati V, Laudisio S, Motta M, Esposito S. Therapeutic Options for Crigler-Najjar Syndrome: A Scoping Review. Int J Mol Sci 2024.","DOI":"10.20944\/preprints202409.1267.v1"},{"key":"4518_CR32","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1016\/j.ajt.2025.08.003","volume":"25","author":"E Tan","year":"2025","unstructured":"Tan E, Ahimsadasan N, Hlaing NKT, Low J, Naimimohasses S, Chen S, Bhat M. The Evolving Role of Liver Transplantation as Enzyme Replacement Therapy in the Era of RNA Nanotherapies. Am J Transplantation: Official J Am Soc Transplantation Am Soc Transpl Surg. 2025;25:2611\u201320.","journal-title":"Am J Transplantation: Official J Am Soc Transplantation Am Soc Transpl Surg"},{"key":"4518_CR33","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.ymthe.2025.03.041","volume":"33","author":"F Puzzo","year":"2025","unstructured":"Puzzo F, Kay MA. The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy. Mol Ther. 2025;33:1966\u201387.","journal-title":"Mol Ther"},{"key":"4518_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s13023-025-03844-8","volume":"20","author":"F Spataro","year":"2025","unstructured":"Spataro F, Solimando AG, Desantis V, Vacca A, Di Girolamo A, Ria R. How to manage hypersensitivity reactions to enzyme replacement therapy in lysosomal storage diseases? Orphanet J Rare Dis. 2025;20:287.","journal-title":"Orphanet J Rare Dis"},{"key":"4518_CR35","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1182\/bloodadvances.2024013059","volume":"8","author":"MV Ragni","year":"2024","unstructured":"Ragni MV, Mead H, de Jong YP, Kaczmarek R, Leavitt AD, Long B, Nugent DJ, Sabatino DE, Fong S, von Drygalski A, et al. Optimizing liver health before and after gene therapy for hemophilia A. Blood Adv. 2024;8:5203\u201312.","journal-title":"Blood Adv"},{"key":"4518_CR36","doi-asserted-by":"publisher","first-page":"e157937","DOI":"10.1172\/JCI157937","volume":"133","author":"W Liu","year":"2023","unstructured":"Liu W, Zhou X, Yao Q, Chen C, Zhang Q, Ding K, Li L, Zeng Z. In situ expansion and reprogramming of Kupffer cells elicit potent tumoricidal immunity against liver metastasis. J Clin Invest. 2023;133:e157937.","journal-title":"J Clin Invest"},{"key":"4518_CR37","first-page":"76","volume":"15","author":"AS Pathania","year":"2025","unstructured":"Pathania AS, Bhat SA, Adepoju LA, Kharbanda KK, Osna NA. Hepatic Macrophages in Chronic Hepatitis B: Balancing Immunity and Pathology. Biology (Basel). 2025;15:76.","journal-title":"Biology (Basel)"},{"key":"4518_CR38","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.cmet.2023.06.013","volume":"35","author":"H Rho","year":"2023","unstructured":"Rho H, Terry AR, Chronis C, Hay N. Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis. Cell Metab. 2023;35:1406\u2013e14231408.","journal-title":"Cell Metab"},{"key":"4518_CR39","doi-asserted-by":"publisher","first-page":"102116","DOI":"10.1016\/j.omtn.2024.102116","volume":"35","author":"E Borroni","year":"2024","unstructured":"Borroni E, Borsotti C, Cirsmaru RA, Kalandadze V, Fama R, Merlin S, Brown B, Follenzi A. Immune tolerance promotion by LSEC-specific lentiviral vector-mediated expression of the transgene regulated by the stabilin-2 promoter. Mol Ther Nucleic Acids. 2024;35:102116.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4518_CR40","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1055\/a-1282-2286","volume":"40","author":"O El-Maarri","year":"2020","unstructured":"El-Maarri O, Jamil MA, Oldenburg J. Molecular Profiling of Liver Sinusoidal Endothelial Cells in Comparison to Hepatocytes: Reflection on Which Cell Type Should Be the Target for Gene Therapy. Hamostaseologie. 2020;40:S26\u201331.","journal-title":"Hamostaseologie"},{"key":"4518_CR41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Givosiran: First Approval. Drugs. 2020;80:335\u20139.","journal-title":"Drugs"},{"key":"4518_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","volume":"81","author":"LJ Scott","year":"2021","unstructured":"Scott LJ, Keam SJ. Lumasiran: First Approval. Drugs. 2021;81:277\u201382.","journal-title":"Drugs"},{"key":"4518_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Inclisiran: First Approval. Drugs. 2021;81:389\u201395.","journal-title":"Drugs"},{"key":"4518_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","volume":"83","author":"YA Heo","year":"2023","unstructured":"Heo YA. Etranacogene Dezaparvovec: First Approval. Drugs. 2023;83:347\u201352.","journal-title":"Drugs"},{"key":"4518_CR45","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","volume":"83","author":"YY Syed","year":"2023","unstructured":"Syed YY. Nedosiran: First Approval. Drugs. 2023;83:1729\u201333.","journal-title":"Drugs"},{"key":"4518_CR46","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s40265-022-01788-y","volume":"82","author":"HA Blair","year":"2022","unstructured":"Blair HA. Valoctocogene Roxaparvovec: First Approval. Drugs. 2022;82:1505\u201310.","journal-title":"Drugs"},{"key":"4518_CR47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon S. Fidanacogene Elaparvovec: First Approval. Drugs. 2024;84:479\u201386.","journal-title":"Drugs"},{"key":"4518_CR48","doi-asserted-by":"crossref","unstructured":"Xue F, Hu Y, Yang R, Sun J, Yang L, Wang X, Yu Z, Zhu T, Zhou H, Zhou Z et al. Chinese guidance for the clinical application of adeno-associated virus vector-based gene therapy for hemophilia B (2025). Blood Sci 2025, 7:e00257.","DOI":"10.1097\/BS9.0000000000000257"},{"key":"4518_CR49","doi-asserted-by":"publisher","first-page":"e114760","DOI":"10.15252\/embj.2023114760","volume":"42","author":"A Sparmann","year":"2023","unstructured":"Sparmann A, Vogel J. RNA-based medicine: from molecular mechanisms to therapy. EMBO J. 2023;42:e114760.","journal-title":"EMBO J"},{"key":"4518_CR50","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12951-023-02044-5","volume":"21","author":"C Wang","year":"2023","unstructured":"Wang C, Pan C, Yong H, Wang F, Bo T, Zhao Y, Ma B, He W, Li M. Emerging non-viral vectors for gene delivery. J Nanobiotechnol. 2023;21:272.","journal-title":"J Nanobiotechnol"},{"key":"4518_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jconrel.2022.01.008","volume":"342","author":"Y Yan","year":"2022","unstructured":"Yan Y, Liu XY, Lu A, Wang XY, Jiang LX, Wang JC. Non-viral vectors for RNA delivery. J Control Release. 2022;342:241\u201379.","journal-title":"J Control Release"},{"key":"4518_CR52","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3390\/pharmaceutics17081074","volume":"17","author":"S Fu","year":"2025","unstructured":"Fu S, Zhu X, Huang F, Chen X. Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization. Pharmaceutics. 2025;17:1074.","journal-title":"Pharmaceutics"},{"key":"4518_CR53","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41541-025-01124-x","volume":"10","author":"AE Zelkoski","year":"2025","unstructured":"Zelkoski AE, Lu Z, Sukumar G, Dalgard C, Said H, Alameh MG, Mitre E, Malloy AMW. Ionizable lipid nanoparticles of mRNA vaccines elicit NF-kappaB and IRF responses through toll-like receptor 4. NPJ Vaccines. 2025;10:73.","journal-title":"NPJ Vaccines"},{"key":"4518_CR54","first-page":"e2306134","volume":"20","author":"N Chaudhary","year":"2024","unstructured":"Chaudhary N, Newby AN, Whitehead KA. Non-Viral RNA Delivery During Pregnancy: Opportunities and Challenges. Small. 2024;20:e2306134.","journal-title":"Small"},{"key":"4518_CR55","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.cell.2018.03.064","volume":"173","author":"M Jiang","year":"2018","unstructured":"Jiang M, Zhang S, Yang Z, Lin H, Zhu J, Liu L, Wang W, Liu S, Liu W, Ma Y, et al. Self-Recognition of an Inducible Host lncRNA by RIG-I Feedback Restricts Innate Immune Response. Cell. 2018;173:906\u2013e919913.","journal-title":"Cell"},{"key":"4518_CR56","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.omtn.2020.05.010","volume":"21","author":"SM Davis","year":"2020","unstructured":"Davis SM, Sousa J, Vangjeli L, Hassler MR, Echeverria D, Knox E, Turanov AA, Alterman JF, Khvorova A. 2\u2019-O-Methyl at 20-mer Guide Strand 3\u2019 Termini May Negatively Affect Target Silencing Activity of Fully Chemically Modified siRNA. Mol Ther Nucleic Acids. 2020;21:266\u201377.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4518_CR57","doi-asserted-by":"publisher","first-page":"19691","DOI":"10.1021\/jacs.3c04744","volume":"145","author":"S Matsuda","year":"2023","unstructured":"Matsuda S, Bala S, Liao JY, Datta D, Mikami A, Woods L, Harp JM, Gilbert JA, Bisbe A, Manoharan RM, et al. Shorter Is Better: The alpha-(l)-Threofuranosyl Nucleic Acid Modification Improves Stability, Potency, Safety, and Ago2 Binding and Mitigates Off-Target Effects of Small Interfering RNAs. J Am Chem Soc. 2023;145:19691\u2013706.","journal-title":"J Am Chem Soc"},{"key":"4518_CR58","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.omtn.2025.102590","volume":"36","author":"M Grogan","year":"2025","unstructured":"Grogan M, Sheikh FH, Sperry BW, Sweetser MT, Capocelli K, Roblin S, Witteles R. Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis. Mol Ther Nucleic Acids. 2025;36:102590.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4518_CR59","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41576-022-00550-0","volume":"24","author":"S He","year":"2023","unstructured":"He S, Valkov E, Cheloufi S, Murn J. The nexus between RNA-binding proteins and their effectors. Nat Rev Genet. 2023;24:276\u201394.","journal-title":"Nat Rev Genet"},{"key":"4518_CR60","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1021\/acs.jmedchem.3c01354","volume":"67","author":"J Kaur","year":"2024","unstructured":"Kaur J, Sharma A, Mundlia P, Sood V, Pandey A, Singh G, Barnwal RP. RNA-Small-Molecule Interaction: Challenging the Undruggable Tag. J Med Chem. 2024;67:4259\u201397.","journal-title":"J Med Chem"},{"key":"4518_CR61","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1124\/pr.120.019554","volume":"72","author":"AM Yu","year":"2020","unstructured":"Yu AM, Choi YH, Tu MJ. RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges. Pharmacol Rev. 2020;72:862\u201398.","journal-title":"Pharmacol Rev"},{"key":"4518_CR62","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41576-023-00645-2","volume":"25","author":"S Delaunay","year":"2024","unstructured":"Delaunay S, Helm M, Frye M. RNA modifications in physiology and disease: towards clinical applications. Nat Rev Genet. 2024;25:104\u201322.","journal-title":"Nat Rev Genet"},{"key":"4518_CR63","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","volume":"23","author":"K Paunovska","year":"2022","unstructured":"Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23:265\u201380.","journal-title":"Nat Rev Genet"},{"key":"4518_CR64","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jconrel.2023.09.032","volume":"363","author":"H Zhu","year":"2023","unstructured":"Zhu H, Luo H, Chang R, Yang Y, Liu D, Ji Y, Qin H, Rong H, Yin J. Protein-based delivery systems for RNA delivery. J Control Release. 2023;363:253\u201374.","journal-title":"J Control Release"},{"key":"4518_CR65","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.3390\/molecules29245997","volume":"29","author":"R Allen","year":"2024","unstructured":"Allen R, Yokota T. Endosomal Escape and Nuclear Localization: Critical Barriers for Therapeutic Nucleic Acids. Molecules. 2024;29:5997.","journal-title":"Molecules"},{"key":"4518_CR66","doi-asserted-by":"crossref","unstructured":"Yadegarazari R, Lotfollahzadeh S, Shabaninejad Z, Pouraghajan K, Rezaei A, Soleymani B, Mohammadi S. Recent Advances in Non-Viral Gene Delivery Systems for Hepatic Gene Therapy. Curr Med Chem 2025.","DOI":"10.2174\/0109298673395530251001155804"},{"key":"4518_CR67","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.addr.2021.05.018","volume":"174","author":"Z Liu","year":"2021","unstructured":"Liu Z, Wang S, Tapeinos C, Torrieri G, Kankanen V, El-Sayed N, Python A, Hirvonen JT, Santos HA. Non-viral nanoparticles for RNA interference: Principles of design and practical guidelines. Adv Drug Deliv Rev. 2021;174:576\u2013612.","journal-title":"Adv Drug Deliv Rev"},{"key":"4518_CR68","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","volume":"17","author":"MA Kotterman","year":"2015","unstructured":"Kotterman MA, Chalberg TW, Schaffer DV. Viral Vectors for Gene Therapy: Translational and Clinical Outlook. Annu Rev Biomed Eng. 2015;17:63\u201389.","journal-title":"Annu Rev Biomed Eng"},{"key":"4518_CR69","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nbt.2612","volume":"31","author":"J Gilleron","year":"2013","unstructured":"Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, Manygoats K, Seifert S, Andree C, Stoter M, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013;31:638\u201346.","journal-title":"Nat Biotechnol"},{"key":"4518_CR70","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1261\/rna.079507.122","volume":"29","author":"SF Dowdy","year":"2023","unstructured":"Dowdy SF. Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem? RNA. 2023;29:396\u2013401.","journal-title":"RNA"},{"key":"4518_CR71","doi-asserted-by":"publisher","first-page":"2404510","DOI":"10.1002\/adfm.202404510","volume":"34","author":"H Liu","year":"2024","unstructured":"Liu H, Chen MZ, Payne T, Porter CJH, Pouton CW, Johnston APR. Beyond the Endosomal Bottleneck: Understanding the Efficiency of mRNA\/LNP Delivery. Adv Funct Mater. 2024;34:2404510.","journal-title":"Adv Funct Mater"},{"key":"4518_CR72","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang X, Liu S, Sun Y, Yu X, Lee SM, Cheng Q, Wei T, Gong J, Robinson J, Zhang D, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc. 2023;18:265\u201391.","journal-title":"Nat Protoc"},{"key":"4518_CR73","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1021\/acs.molpharmaceut.5c00918","volume":"22","author":"D Dou","year":"2025","unstructured":"Dou D, Lu J, Sangchen P, Guo C, Li D, He F, Zhu X, Zhang X, Chen X. Pharmacokinetics, Biodistribution, Immunogenicity, and Model-Informed-Based PK\/PD Model of a Next-Generation Advanced Novel Gene Therapy for Hemophilia. Mol Pharm. 2025;22:6381\u201394.","journal-title":"Mol Pharm"},{"key":"4518_CR74","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.ymthe.2025.03.056","volume":"33","author":"AM Nisanov","year":"2025","unstructured":"Nisanov AM, Rivera de Jesus JA, Schaffer DV. Advances in AAV capsid engineering: Integrating rational design, directed evolution and machine learning. Mol Ther. 2025;33:1937\u201345.","journal-title":"Mol Ther"},{"key":"4518_CR75","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis PR, Felgner PL. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat Rev Drug Discov. 2024;23:709\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"4518_CR76","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1021\/acs.molpharmaceut.2c00032","volume":"19","author":"HH Ly","year":"2022","unstructured":"Ly HH, Daniel S, Soriano SKV, Kis Z, Blakney AK. Optimization of Lipid Nanoparticles for saRNA Expression and Cellular Activation Using a Design-of-Experiment Approach. Mol Pharm. 2022;19:1892\u2013905.","journal-title":"Mol Pharm"},{"key":"4518_CR77","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.livres.2025.04.006","volume":"9","author":"C Wang","year":"2025","unstructured":"Wang C, Fan M, Liu J, Guo X, Tan Z, Huang X, Li Z, Liu X, Zhang Y, Feng J, et al. Efficient AAV8 delivery to the liver via isolated hepatic perfusion and analysis of hepatic lobule transduction patterns. Liver Res. 2025;9:313\u201323.","journal-title":"Liver Res"},{"key":"4518_CR78","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1038\/s41467-025-57382-9","volume":"16","author":"R Ferriero","year":"2025","unstructured":"Ferriero R, Bruno G, Padula A, Pisano S, Boffa I, Gargaro M, Imperatore T, Battipaglia M, Vivenzio S, Perna C, et al. Impact of liver fibrosis on AAV-mediated gene transfer to mouse hepatocytes. Nat Commun. 2025;16:2118.","journal-title":"Nat Commun"},{"key":"4518_CR79","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/v17020276","volume":"17","author":"P Hu","year":"2025","unstructured":"Hu P, Hao Y, Tang W, Diering GH, Zou F, Kafri T. Analysis of Hepatic Lentiviral Vector Transduction: Implications for Preclinical Studies and Clinical Gene Therapy Protocols. Viruses. 2025;17:276.","journal-title":"Viruses"},{"key":"4518_CR80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jimd.12709","volume":"47","author":"J Baruteau","year":"2024","unstructured":"Baruteau J, Brunetti-Pierri N, Gissen P. Liver-directed gene therapy for inherited metabolic diseases. J Inherit Metab Dis. 2024;47:9\u201321.","journal-title":"J Inherit Metab Dis"},{"key":"4518_CR81","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018;24:927\u201330.","journal-title":"Nat Med"},{"key":"4518_CR82","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-1-0716-1601-7_16","volume":"2352","author":"I Canals","year":"2021","unstructured":"Canals I, Ahlenius H. CRISPR\/Cas9 Genome Engineering in Human Pluripotent Stem Cells for Modeling of Neurological Disorders. Methods Mol Biol. 2021;2352:237\u201351.","journal-title":"Methods Mol Biol"},{"key":"4518_CR83","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41588-020-0623-4","volume":"52","author":"OM Enache","year":"2020","unstructured":"Enache OM, Rendo V, Abdusamad M, Lam D, Davison D, Pal S, Currimjee N, Hess J, Pantel S, Nag A, et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020;52:662\u20138.","journal-title":"Nat Genet"},{"key":"4518_CR84","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nbt.4172","volume":"36","author":"LW Koblan","year":"2018","unstructured":"Koblan LW, Doman JL, Wilson C, Levy JM, Tay T, Newby GA, Maianti JP, Raguram A, Liu DR. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat Biotechnol. 2018;36:843\u20136.","journal-title":"Nat Biotechnol"},{"key":"4518_CR85","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","volume":"33","author":"SQ Tsai","year":"2015","unstructured":"Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, Wyvekens N, Khayter C, Iafrate AJ, Le LP, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015;33:187\u201397.","journal-title":"Nat Biotechnol"},{"key":"4518_CR86","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nmeth.4278","volume":"14","author":"SQ Tsai","year":"2017","unstructured":"Tsai SQ, Nguyen NT, Malagon-Lopez J, Topkar VV, Aryee MJ, Joung JK. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nat Methods. 2017;14:607\u201314.","journal-title":"Nat Methods"},{"key":"4518_CR87","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.aav9023","volume":"364","author":"B Wienert","year":"2019","unstructured":"Wienert B, Wyman SK, Richardson CD, Yeh CD, Akcakaya P, Porritt MJ, Morlock M, Vu JT, Kazane KR, Watry HL, et al. Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq. Science. 2019;364:286\u20139.","journal-title":"Science"},{"key":"4518_CR88","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","volume":"30","author":"DE Sabatino","year":"2022","unstructured":"Sabatino DE, Bushman FD, Chandler RJ, Crystal RG, Davidson BL, Dolmetsch R, Eggan KC, Gao G, Gil-Farina I, Kay MA, et al. Evaluating the state of the science for adeno-associated virus integration: An integrated perspective. Mol Ther. 2022;30:2646\u201363.","journal-title":"Mol Ther"},{"key":"4518_CR89","doi-asserted-by":"publisher","first-page":"1143157","DOI":"10.3389\/fbioe.2023.1143157","volume":"11","author":"C Guo","year":"2023","unstructured":"Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR\/Cas9 gene editing. Front Bioeng Biotechnol. 2023;11:1143157.","journal-title":"Front Bioeng Biotechnol"},{"key":"4518_CR90","doi-asserted-by":"publisher","first-page":"609650","DOI":"10.3389\/fgeed.2020.609650","volume":"2","author":"G Pavani","year":"2020","unstructured":"Pavani G, Amendola M. Targeted Gene Delivery: Where to Land. Front Genome Ed. 2020;2:609650.","journal-title":"Front Genome Ed"},{"key":"4518_CR91","doi-asserted-by":"publisher","first-page":"101731","DOI":"10.1016\/j.smim.2023.101731","volume":"66","author":"MC Castiello","year":"2023","unstructured":"Castiello MC, Ferrari S, Villa A. Correcting inborn errors of immunity: From viral mediated gene addition to gene editing. Semin Immunol. 2023;66:101731.","journal-title":"Semin Immunol"},{"key":"4518_CR92","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijpharm.2019.04.049","volume":"564","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Lee RJ, Liu L, Dong S, Zhang J, Zhang Y, Yao Y, Lu J, Meng Q, Xie J, Teng L. Multifunctional drug carrier based on PEI derivatives loaded with small interfering RNA for therapy of liver cancer. Int J Pharm. 2019;564:214\u201324.","journal-title":"Int J Pharm"},{"key":"4518_CR93","first-page":"23","volume":"1","author":"V Kafil","year":"2011","unstructured":"Kafil V, Omidi Y. Cytotoxic impacts of linear and branched polyethylenimine nanostructures in a431 cells. Bioimpacts. 2011;1:23\u201330.","journal-title":"Bioimpacts"},{"key":"4518_CR94","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.2174\/0929867325666181031094759","volume":"26","author":"F Hao","year":"2019","unstructured":"Hao F, Li Y, Zhu J, Sun J, Marshall B, Lee RJ, Teng L, Yang Z, Xie J. Polyethylenimine-based Formulations for Delivery of Oligonucleotides. Curr Med Chem. 2019;26:2264\u201384.","journal-title":"Curr Med Chem"},{"key":"4518_CR95","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"4518_CR96","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1021\/acs.molpharmaceut.7b00507","volume":"14","author":"D Bamberger","year":"2017","unstructured":"Bamberger D, Hobernik D, Konhauser M, Bros M, Wich PR. Surface Modification of Polysaccharide-Based Nanoparticles with PEG and Dextran and the Effects on Immune Cell Binding and Stimulatory Characteristics. Mol Pharm. 2017;14:4403\u201316.","journal-title":"Mol Pharm"},{"key":"4518_CR97","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.2174\/1381612821666151027152907","volume":"21","author":"X Wang","year":"2015","unstructured":"Wang X, Niu D, Hu C, Li P. Polyethyleneimine-Based Nanocarriers for Gene Delivery. Curr Pharm Des. 2015;21:6140\u201356.","journal-title":"Curr Pharm Des"},{"key":"4518_CR98","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.1021\/acs.biomac.5c01014","volume":"26","author":"B Zhao","year":"2025","unstructured":"Zhao B, Zhang X, Bilbao D, Satta S, Steele NS, Chen J, Fu S, Bickle MS, Gu J, Levkovsky IO, et al. Glutathione-Responsive Polyhomocysteine Derivatives with Ultralow Toxicity toward Therapeutic Delivery. Biomacromolecules. 2025;26:7470\u201383.","journal-title":"Biomacromolecules"},{"key":"4518_CR99","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1039\/D4MD00652F","volume":"16","author":"F Ramirez-Cortes","year":"2025","unstructured":"Ramirez-Cortes F, Menova P. Hepatocyte targeting via the asialoglycoprotein receptor. RSC Med Chem. 2025;16:525\u201344.","journal-title":"RSC Med Chem"},{"key":"4518_CR100","doi-asserted-by":"publisher","first-page":"e2304263","DOI":"10.1002\/smll.202304263","volume":"19","author":"R Hincapie","year":"2023","unstructured":"Hincapie R, Bhattacharya S, Baksh MM, Sanhueza CA, Echeverri ES, Kim H, Paunovska K, Podilapu AR, Xu M, Dahlman JE, Finn MG. Multivalent Targeting of the Asialoglycoprotein Receptor by Virus-Like Particles. Small. 2023;19:e2304263.","journal-title":"Small"},{"key":"4518_CR101","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1021\/bc970098f","volume":"8","author":"MA Zanta","year":"1997","unstructured":"Zanta MA, Boussif O, Adib A, Behr JP. In vitro gene delivery to hepatocytes with galactosylated polyethylenimine. Bioconjug Chem. 1997;8:839\u201344.","journal-title":"Bioconjug Chem"},{"key":"4518_CR102","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0168-3659(02)00458-3","volume":"88","author":"K Kunath","year":"2003","unstructured":"Kunath K, von Harpe A, Fischer D, Kissel T. Galactose-PEI-DNA complexes for targeted gene delivery: degree of substitution affects complex size and transfection efficiency. J Control Release. 2003;88:159\u201372.","journal-title":"J Control Release"},{"key":"4518_CR103","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.2147\/IJN.S532246","volume":"20","author":"KM Thalij","year":"2025","unstructured":"Thalij KM, You HW, Aher KB, Bhavar GB, Kumbhar ST, Habeeb M. Advances in Lipid-Based Nanomedicine: Pathway Specific siRNA Therapy and Optimizing Delivery for Hepatocellular Carcinoma. Int J Nanomed. 2025;20:10541\u201366.","journal-title":"Int J Nanomed"},{"key":"4518_CR104","doi-asserted-by":"publisher","first-page":"102801","DOI":"10.1016\/j.omtn.2025.102801","volume":"37","author":"ZA Huang","year":"2026","unstructured":"Huang ZA, Li ZM, Wang J, Ji GS, Gao ZC, Chen AF, Tian ZK, Yu F, Song GS. Ribofuranose-based GalNAc-conjugated siRNA enhances the liver-targeted delivery and elicits robust RNAi-mediated gene silencing. Mol Ther Nucleic Acids. 2026;37:102801.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4518_CR105","doi-asserted-by":"publisher","first-page":"122559","DOI":"10.1016\/j.biomaterials.2024.122559","volume":"308","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Cai SS, Ma J, Cheng L, Wei C, Aggarwal A, Toh WH, Shin C, Shen R, Kong J, et al. Optimization of lipid nanoparticles for gene editing of the liver via intraduodenal delivery. Biomaterials. 2024;308:122559.","journal-title":"Biomaterials"},{"key":"4518_CR106","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3390\/cancers11091265","volume":"11","author":"SC Reghupaty","year":"2019","unstructured":"Reghupaty SC, Sarkar D. Current Status of Gene Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2019;11:1265.","journal-title":"Cancers (Basel)"},{"key":"4518_CR107","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.3390\/ijms22062912","volume":"22","author":"P Tarach","year":"2021","unstructured":"Tarach P, Janaszewska A. Recent Advances in Preclinical Research Using PAMAM Dendrimers for Cancer Gene Therapy. Int J Mol Sci. 2021;22:2912.","journal-title":"Int J Mol Sci"},{"key":"4518_CR108","doi-asserted-by":"publisher","first-page":"33412","DOI":"10.1021\/acsami.6b08153","volume":"8","author":"R Devulapally","year":"2016","unstructured":"Devulapally R, Foygel K, Sekar TV, Willmann JK, Paulmurugan R. Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy. ACS Appl Mater Interfaces. 2016;8:33412\u201322.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4518_CR109","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2478\/s11658-009-0003-7","volume":"14","author":"S Diez","year":"2009","unstructured":"Diez S, Migueliz I, Tros de Ilarduya C. Targeted cationic poly(D,L-lactic-co-glycolic acid) nanoparticles for gene delivery to cultured cells. Cell Mol Biol Lett. 2009;14:347\u201362.","journal-title":"Cell Mol Biol Lett"},{"key":"4518_CR110","first-page":"903","volume":"10","author":"KR Jyothi","year":"2015","unstructured":"Jyothi KR, Beloor J, Jo A, Nguyen MN, Choi TG, Kim JH, Akter S, Lee SK, Maeng CH, Baik HH, et al. Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication. Int J Nanomed. 2015;10:903\u201321.","journal-title":"Int J Nanomed"},{"key":"4518_CR111","doi-asserted-by":"publisher","first-page":"e2409569122","DOI":"10.1073\/pnas.2409569122","volume":"122","author":"K Gentry","year":"2025","unstructured":"Gentry K, Lian L, Kim H, Celik O, Jones C, Podilapu AR, Shakked A, Loughrey D, Zenhausern R, Jang B, et al. Glycolipid nanoparticles target the spleen and detarget the liver without charge. Proc Natl Acad Sci U S A. 2025;122:e2409569122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4518_CR112","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jconrel.2023.11.017","volume":"364","author":"C Geng","year":"2023","unstructured":"Geng C, Zhou K, Yan Y, Li C, Ni B, Liu J, Wang Y, Zhang X, Wang D, Lv L, et al. A preparation method for mRNA-LNPs with improved properties. J Control Release. 2023;364:632\u201343.","journal-title":"J Control Release"},{"key":"4518_CR113","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s43586-022-00104-y","volume":"2","author":"BB Mendes","year":"2022","unstructured":"Mendes BB, Conniot J, Avital A, Yao D, Jiang X, Zhou X, Sharf-Pauker N, Xiao Y, Adir O, Liang H, et al. Nanodelivery of nucleic acids. Nat Rev Methods Primers. 2022;2:24.","journal-title":"Nat Rev Methods Primers"},{"key":"4518_CR114","doi-asserted-by":"publisher","first-page":"8698","DOI":"10.1021\/acs.jpcb.5b02891","volume":"119","author":"AK Leung","year":"2015","unstructured":"Leung AK, Tam YY, Chen S, Hafez IM, Cullis PR. Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems. J Phys Chem B. 2015;119:8698\u2013706.","journal-title":"J Phys Chem B"},{"key":"4518_CR115","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1038\/mtna.2012.28","volume":"1","author":"NM Belliveau","year":"2012","unstructured":"Belliveau NM, Huft J, Lin PJ, Chen S, Leung AK, Leaver TJ, Wild AW, Lee JB, Taylor RJ, Tam YK, et al. Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol Ther Nucleic Acids. 2012;1:e37.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4518_CR116","doi-asserted-by":"crossref","unstructured":"Forrester J, Davidson CG, Blair M, Donlon L, McLoughlin DM, Obiora CR, Stockdale H, Thomas B, Nutman M, Brockbank S et al. Low-Cost Microfluidic Mixers: Are They up to the Task? Pharmaceutics 2025, 17.","DOI":"10.3390\/pharmaceutics17050566"},{"key":"4518_CR117","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1021\/acs.nanolett.1c01353","volume":"21","author":"SJ Shepherd","year":"2021","unstructured":"Shepherd SJ, Warzecha CC, Yadavali S, El-Mayta R, Alameh MG, Wang L, Weissman D, Wilson JM, Issadore D, Mitchell MJ. Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device. Nano Lett. 2021;21:5671\u201380.","journal-title":"Nano Lett"},{"key":"4518_CR118","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1039\/D3LC00821E","volume":"24","author":"S Mehraji","year":"2024","unstructured":"Mehraji S, DeVoe DL. Microfluidic synthesis of lipid-based nanoparticles for drug delivery: recent advances and opportunities. Lab Chip. 2024;24:1154\u201374.","journal-title":"Lab Chip"},{"key":"4518_CR119","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen J, Du X, Butler D, Eltepu L, Matsuda S, Narayanannair JK, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012;51:8529\u201333.","journal-title":"Angew Chem Int Ed Engl"},{"key":"4518_CR120","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier MA, Jayaraman M, Matsuda S, Liu J, Barros S, Querbes W, Tam YK, Ansell SM, Kumar V, Qin J, et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther. 2013;21:1570\u20138.","journal-title":"Mol Ther"},{"key":"4518_CR121","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Y Eygeris","year":"2022","unstructured":"Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of Lipid Nanoparticles for RNA Delivery. Acc Chem Res. 2022;55:2\u201312.","journal-title":"Acc Chem Res"},{"key":"4518_CR122","first-page":"100305","volume":"8","author":"AS Alfutaimani","year":"2024","unstructured":"Alfutaimani AS, Alharbi NK, A SA, Aldayel AAA. Exploring the landscape of Lipid Nanoparticles (LNPs): A comprehensive review of LNPs types and biological sources of lipids. Int J Pharm X. 2024;8:100305.","journal-title":"Int J Pharm X"},{"key":"4518_CR123","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis PR, Hope MJ. Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol Ther. 2017;25:1467\u201375.","journal-title":"Mol Ther"},{"key":"4518_CR124","doi-asserted-by":"publisher","first-page":"108560","DOI":"10.1016\/j.ymgme.2024.108560","volume":"143","author":"KA Coughlan","year":"2024","unstructured":"Coughlan KA, Eybye M, Henderson N, DeAntonis CM, Frassetto A, Hanahoe E, Ketova T, Jacquinet E, Presnyak V, Jain R, et al. Improved therapeutic efficacy in two mouse models of methylmalonic acidemia (MMA) using a second-generation mRNA therapy. Mol Genet Metab. 2024;143:108560.","journal-title":"Mol Genet Metab"},{"key":"4518_CR125","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ymthe.2024.10.003","volume":"33","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Chen S, Hsiao S, Zhang H, Xie D, Wang ZJ, Ren W, Liu M, Liao J, Wu Y. Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption. Mol Ther. 2025;33:104\u201318.","journal-title":"Mol Ther"},{"key":"4518_CR126","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/jimd.12660","volume":"46","author":"A Samanta","year":"2023","unstructured":"Samanta A, George N, Arnaoutova I, Chen HD, Mansfield BC, Hart C, Carlo T, Chou JY. CRISPR\/Cas9-based double-strand oligonucleotide insertion strategy corrects metabolic abnormalities in murine glycogen storage disease type-Ia. J Inherit Metab Dis. 2023;46:1147\u201358.","journal-title":"J Inherit Metab Dis"},{"key":"4518_CR127","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.ymthe.2019.04.017","volume":"27","author":"J Cao","year":"2019","unstructured":"Cao J, An D, Galduroz M, Zhuo J, Liang S, Eybye M, Frassetto A, Kuroda E, Funahashi A, Santana J, et al. mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency. Mol Ther. 2019;27:1242\u201351.","journal-title":"Mol Ther"},{"key":"4518_CR128","doi-asserted-by":"publisher","first-page":"100300","DOI":"10.1016\/j.jhepr.2021.100300","volume":"3","author":"S Maestro","year":"2021","unstructured":"Maestro S, Weber ND, Zabaleta N, Aldabe R, Gonzalez-Aseguinolaza G. Novel vectors and approaches for gene therapy in liver diseases. JHEP Rep. 2021;3:100300.","journal-title":"JHEP Rep"},{"key":"4518_CR129","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1089\/hum.2024.047","volume":"35","author":"JA Greig","year":"2024","unstructured":"Greig JA, Jennis M, Dandekar A, Chorazeczewski JK, Param N, So M, Nayal M, Bell P, Coughlan K, Choi M, et al. Lipid Nanoparticle mRNA Therapy Improves Survival and Reduces Serum Branched-Chain Amino Acids in Mouse Models of Maple Syrup Urine Disease. Hum Gene Ther. 2024;35:726\u201333.","journal-title":"Hum Gene Ther"},{"key":"4518_CR130","doi-asserted-by":"publisher","first-page":"21150","DOI":"10.1073\/pnas.1906182116","volume":"116","author":"B Truong","year":"2019","unstructured":"Truong B, Allegri G, Liu XB, Burke KE, Zhu X, Cederbaum SD, Haberle J, Martini PGV, Lipshutz GS. Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency. Proc Natl Acad Sci U S A. 2019;116:21150\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4518_CR131","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.omtn.2023.06.023","volume":"33","author":"K Yamazaki","year":"2023","unstructured":"Yamazaki K, Kubara K, Ishii S, Kondo K, Suzuki Y, Miyazaki T, Mitsuhashi K, Ito M, Tsukahara K. Lipid nanoparticle-targeted mRNA formulation as a treatment for ornithine-transcarbamylase deficiency model mice. Mol Ther Nucleic Acids. 2023;33:210\u201326.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4518_CR132","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.jhep.2020.12.010","volume":"74","author":"G Wei","year":"2021","unstructured":"Wei G, Cao J, Huang P, An P, Badlani D, Vaid KA, Zhao S, Wang DQ, Zhuo J, Yin L, et al. Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB\/c.Abcb4(-\/-) mouse model of PFIC3. J Hepatol. 2021;74:1416\u201328.","journal-title":"J Hepatol"},{"key":"4518_CR133","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","volume":"21","author":"D An","year":"2017","unstructured":"An D, Schneller JL, Frassetto A, Liang S, Zhu X, Park JS, Theisen M, Hong SJ, Zhou J, Rajendran R, et al. Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia. Cell Rep. 2017;21:3548\u201358.","journal-title":"Cell Rep"},{"key":"4518_CR134","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ebiom.2019.07.003","volume":"45","author":"D An","year":"2019","unstructured":"An D, Frassetto A, Jacquinet E, Eybye M, Milano J, DeAntonis C, Nguyen V, Laureano R, Milton J, Sabnis S, et al. Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia. EBioMedicine. 2019;45:519\u201328.","journal-title":"EBioMedicine"},{"key":"4518_CR135","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379:11\u201321.","journal-title":"N Engl J Med"},{"key":"4518_CR136","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jconrel.2022.11.036","volume":"353","author":"Y Sakurai","year":"2023","unstructured":"Sakurai Y, Yoshikawa K, Arai K, Kazaoka A, Aoki S, Ito K, Nakai Y, Tange K, Furihata T, Tanaka H, Akita H. siRNA delivery to lymphatic endothelial cells via ApoE-mediated uptake by lipid nanoparticles. J Control Release. 2023;353:125\u201333.","journal-title":"J Control Release"},{"key":"4518_CR137","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","volume":"52","author":"JA Kulkarni","year":"2019","unstructured":"Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics. Acc Chem Res. 2019;52:2435\u201344.","journal-title":"Acc Chem Res"},{"key":"4518_CR138","doi-asserted-by":"publisher","first-page":"e2020401118","DOI":"10.1073\/pnas.2020401118","volume":"118","author":"M Qiu","year":"2021","unstructured":"Qiu M, Glass Z, Chen J, Haas M, Jin X, Zhao X, Rui X, Ye Z, Li Y, Zhang F, Xu Q. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3. Proc Natl Acad Sci U S A. 2021;118:e2020401118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4518_CR139","doi-asserted-by":"publisher","first-page":"27","DOI":"10.17925\/HI.2023.17.1.27","volume":"17","author":"A Ioannou","year":"2023","unstructured":"Ioannou A, Fontana M, Gillmore JD. Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy. Heart Int. 2023;17:27\u201335.","journal-title":"Heart Int"},{"key":"4518_CR140","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2024.4631","volume":"82","author":"D Adams","year":"2025","unstructured":"Adams D, Wixner J, Polydefkis M, Berk JL, Conceicao IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, et al. Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. JAMA Neurol. 2025;82:228\u201336.","journal-title":"JAMA Neurol"},{"key":"4518_CR141","doi-asserted-by":"publisher","first-page":"175909141771920","DOI":"10.1177\/1759091417719201","volume":"9","author":"FM Marottoli","year":"2017","unstructured":"Marottoli FM, Katsumata Y, Koster KP, Thomas R, Fardo DW, Tai LM. Peripheral Inflammation, Apolipoprotein E4, and Amyloid-beta Interact to Induce Cognitive and Cerebrovascular Dysfunction. ASN Neuro. 2017;9:1759091417719201.","journal-title":"ASN Neuro"},{"key":"4518_CR142","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1194\/jlr.M500114-JLR200","volume":"46","author":"J Ruiz","year":"2005","unstructured":"Ruiz J, Kouiavskaia D, Migliorini M, Robinson S, Saenko EL, Gorlatova N, Li D, Lawrence D, Hyman BT, Weisgraber KH, Strickland DK. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res. 2005;46:1721\u201331.","journal-title":"J Lipid Res"},{"key":"4518_CR143","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.3390\/ijms22095030","volume":"22","author":"M Kim","year":"2021","unstructured":"Kim M, Bezprozvanny I. Differences in Recycling of Apolipoprotein E3 and E4-LDL Receptor Complexes-A Mechanistic Hypothesis. Int J Mol Sci. 2021;22:5030.","journal-title":"Int J Mol Sci"},{"key":"4518_CR144","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/jnc.15665","volume":"163","author":"J Sepulveda","year":"2022","unstructured":"Sepulveda J, Luo N, Nelson M, Ng CAS, Rebeck GW. Independent APOE4 knock-in mouse models display reduced brain APOE protein, altered neuroinflammation, and simplification of dendritic spines. J Neurochem. 2022;163:247\u201359.","journal-title":"J Neurochem"},{"key":"4518_CR145","doi-asserted-by":"publisher","first-page":"189318","DOI":"10.1016\/j.bbcan.2025.189318","volume":"1880","author":"D Ghosh","year":"2025","unstructured":"Ghosh D, Guin A, Kumar A, Das A, Paul S. Comprehensive insights of etiological drivers of hepatocellular carcinoma: Fostering targeted nano delivery to anti-cancer regimes. Biochim Biophys Acta Rev Cancer. 2025;1880:189318.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"4518_CR146","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1016\/j.ymthe.2025.06.027","volume":"33","author":"MJ Limeres","year":"2025","unstructured":"Limeres MJ, Gambaro R, Svensson M, Fraude-El Ghazi S, Pretsch L, Frank D, Islan GA, Berti IR, Bros M, Tam YK, et al. mRNA-LNP vaccines against hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models. Mol Ther. 2025;33:4156\u201374.","journal-title":"Mol Ther"},{"key":"4518_CR147","doi-asserted-by":"publisher","first-page":"eabc9450","DOI":"10.1126\/sciadv.abc9450","volume":"6","author":"D Rosenblum","year":"2020","unstructured":"Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, Schubert MS, Friedmann-Morvinski D, Cohen ZR, Behlke MA, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv. 2020;6:eabc9450.","journal-title":"Sci Adv"},{"key":"4518_CR148","doi-asserted-by":"publisher","first-page":"1637958","DOI":"10.3389\/fphar.2025.1637958","volume":"16","author":"CE Wang","year":"2025","unstructured":"Wang CE, Zhen D, Yang L, Li G. Clinical development prospects of siRNA drugs for tumor therapy: analysis of clinical trial registration data from 2004 to 2024. Front Pharmacol. 2025;16:1637958.","journal-title":"Front Pharmacol"},{"key":"4518_CR149","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","volume":"13","author":"Y Yin","year":"2024","unstructured":"Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S, Xu X, Nie Y, Fan D, Wu K, Xia L. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Exp Hematol Oncol. 2024;13:72.","journal-title":"Exp Hematol Oncol"},{"key":"4518_CR150","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12951-025-03209-0","volume":"23","author":"J Pan","year":"2025","unstructured":"Pan J, Wang Y, Chen Y, Zhang C, Deng H, Lu J, Chen W. Emerging strategies against accelerated blood clearance phenomenon of nanocarrier drug delivery systems. J Nanobiotechnol. 2025;23:138.","journal-title":"J Nanobiotechnol"},{"key":"4518_CR151","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.3390\/ijms25073595","volume":"25","author":"T de Bakos","year":"2024","unstructured":"Bakos T, Meszaros T, Kozma GT, Berenyi P, Facsko R, Farkas H, Dezsi L, Heirman C, de Koker S, Schiffelers R, et al. mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions. Int J Mol Sci. 2024;25:3595.","journal-title":"Int J Mol Sci"},{"key":"4518_CR152","doi-asserted-by":"publisher","first-page":"8769","DOI":"10.2147\/IJN.S462213","volume":"19","author":"SG Shaji","year":"2024","unstructured":"Shaji SG, Patel P, Mamani UF, Guo Y, Koirala S, Lin CY, Alahmari M, Omoscharka E, Cheng K. Delivery of a STING Agonist Using Lipid Nanoparticles Inhibits Pancreatic Cancer Growth. Int J Nanomed. 2024;19:8769\u201378.","journal-title":"Int J Nanomed"},{"key":"4518_CR153","doi-asserted-by":"publisher","first-page":"102190","DOI":"10.1016\/j.mtbio.2025.102190","volume":"34","author":"R Wu","year":"2025","unstructured":"Wu R, Wang J, Li D, Li A, Yoo KH, Liu Z, Wei W, Wang Z, Feng D. Advances in nanomaterials for enhancing cGAS-STING pathway mediated anti-tumor treatment. Mater Today Bio. 2025;34:102190.","journal-title":"Mater Today Bio"},{"key":"4518_CR154","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1089\/hum.2016.160","volume":"27","author":"LM Kattenhorn","year":"2016","unstructured":"Kattenhorn LM, Tipper CH, Stoica L, Geraghty DS, Wright TL, Clark KR, Wadsworth SC. Adeno-Associated Virus Gene Therapy for Liver Disease. Hum Gene Ther. 2016;27:947\u201361.","journal-title":"Hum Gene Ther"},{"key":"4518_CR155","doi-asserted-by":"crossref","unstructured":"Shahrukh M, Sweeney JR, Del Rio T, Ozsolak F. Metadata assessment of non-human primate studies of AAV9 uncovers potential tissue specific variation in expression efficiency. Gene Ther 2026.","DOI":"10.1038\/s41434-025-00589-8"},{"key":"4518_CR156","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1055\/a-2751-7625","volume":"46","author":"W Miesbach","year":"2026","unstructured":"Miesbach W. Gene Therapy of Haemophilia: Current Status and Future Directions. Hamostaseologie. 2026;46:10\u20136.","journal-title":"Hamostaseologie"},{"key":"4518_CR157","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41392-024-01871-8","volume":"9","author":"W Zai","year":"2024","unstructured":"Zai W, Yang M, Jiang K, Guan J, Wang H, Hu K, Huang C, Chen J, Fu W, Zhan C, Yuan Z. Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection. Signal Transduct Target Ther. 2024;9:150.","journal-title":"Signal Transduct Target Ther"},{"key":"4518_CR158","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","volume":"33","author":"BJ Byrne","year":"2025","unstructured":"Byrne BJ, Flanigan KM, Matesanz SE, Finkel RS, Waldrop MA, D\u2019Ambrosio ES, Johnson NE, Smith BK, B\u00f6nnemann C, Carrig S, et al. Current clinical applications of AAV-mediated gene therapy. Mol Therapy: J Am Soc Gene Therapy. 2025;33:2479\u2013516.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"4518_CR159","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9:78.","journal-title":"Signal Transduct Target Ther"},{"key":"4518_CR160","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2174\/1566523024605627","volume":"2","author":"RA Owens","year":"2002","unstructured":"Owens RA. Second generation adeno-associated virus type 2-based gene therapy systems with the potential for preferential integration into AAVS1. Curr Gene Ther. 2002;2:145\u201359.","journal-title":"Curr Gene Ther"},{"key":"4518_CR161","doi-asserted-by":"crossref","unstructured":"Thomas H, Carlisle RC. Progress in Gene Therapy for Hereditary Tyrosinemia Type 1. Pharmaceutics 2025, 17.","DOI":"10.3390\/pharmaceutics17030387"},{"key":"4518_CR162","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/microorganisms12020310","volume":"12","author":"Y Chen","year":"2024","unstructured":"Chen Y, Hu S, Lee W, Walsh N, Iozza K, Huang N, Preston G, Drouin LM, Jia N, Deng J, et al. A Comprehensive Study of the Effects by Sequence Truncation within Inverted Terminal Repeats (ITRs) on the Productivity, Genome Packaging, and Potency of AAV Vectors. Microorganisms. 2024;12:310.","journal-title":"Microorganisms"},{"key":"4518_CR163","doi-asserted-by":"publisher","first-page":"118300","DOI":"10.1016\/j.biopha.2025.118300","volume":"189","author":"PA Lalys","year":"2025","unstructured":"Lalys PA, Bourdon A, Bouzelha M, Alvarez-Dorta D, Pavageau K, Girard T, Peumery R, Bouchouireb Z, Marchand M, Mellet A, et al. Advancing liver gene therapy: Enhanced transduction with GalNAc-bioconjugated rAAV capsids. Biomed Pharmacother. 2025;189:118300.","journal-title":"Biomed Pharmacother"},{"key":"4518_CR164","doi-asserted-by":"publisher","first-page":"eaba3312","DOI":"10.1126\/scitranslmed.aba3312","volume":"12","author":"M Cabanes-Creus","year":"2020","unstructured":"Cabanes-Creus M, Hallwirth CV, Westhaus A, Ng BH, Liao SHY, Zhu E, Navarro RG, Baltazar G, Drouyer M, Scott S, et al. Restoring the natural tropism of AAV2 vectors for human liver. Sci Transl Med. 2020;12:eaba3312.","journal-title":"Sci Transl Med"},{"key":"4518_CR165","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature16465","volume":"530","author":"S Pillay","year":"2016","unstructured":"Pillay S, Meyer NL, Puschnik AS, Davulcu O, Diep J, Ishikawa Y, Jae LT, Wosen JE, Nagamine CM, Chapman MS, Carette JE. An essential receptor for adeno-associated virus infection. Nature. 2016;530:108\u201312.","journal-title":"Nature"},{"key":"4518_CR166","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1089\/hum.2022.176","volume":"34","author":"J Rana","year":"2023","unstructured":"Rana J, Marsic D, Zou C, Munoz-Melero M, Li X, Kondratov O, Li N, de Jong YP, Zolotukhin S, Biswas M. Characterization of a Bioengineered AAV3B Capsid Variant with Enhanced Hepatocyte Tropism and Immune Evasion. Hum Gene Ther. 2023;34:289\u2013302.","journal-title":"Hum Gene Ther"},{"key":"4518_CR167","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.omtm.2021.04.010","volume":"21","author":"M Cabanes-Creus","year":"2021","unstructured":"Cabanes-Creus M, Navarro RG, Liao SHY, Baltazar G, Drouyer M, Zhu E, Scott S, Luong C, Wilson LOW, Alexander IE, Lisowski L. Single amino acid insertion allows functional transduction of murine hepatocytes with human liver tropic AAV capsids. Mol Ther Methods Clin Dev. 2021;21:607\u201320.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR168","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1128\/JVI.80.9.4610-4622.2006","volume":"80","author":"D Liebl","year":"2006","unstructured":"Liebl D, Difato F, Hornikova L, Mannova P, Stokrova J, Forstova J. Mouse polyomavirus enters early endosomes, requires their acidic pH for productive infection, and meets transferrin cargo in Rab11-positive endosomes. J Virol. 2006;80:4610\u201322.","journal-title":"J Virol"},{"key":"4518_CR169","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/mmi.14909","volume":"118","author":"UF Greber","year":"2022","unstructured":"Greber UF, Suomalainen M. Adenovirus entry: Stability, uncoating, and nuclear import. Mol Microbiol. 2022;118:309\u201320.","journal-title":"Mol Microbiol"},{"key":"4518_CR170","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/sj.gt.3302283","volume":"11","author":"L Zhong","year":"2004","unstructured":"Zhong L, Li W, Yang Z, Chen L, Li Y, Qing K, Weigel-Kelley KA, Yoder MC, Shou W, Srivastava A. Improved transduction of primary murine hepatocytes by recombinant adeno-associated virus 2 vectors in vivo. Gene Ther. 2004;11:1165\u20139.","journal-title":"Gene Ther"},{"key":"4518_CR171","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.ymthe.2025.01.041","volume":"33","author":"CJ Walkey","year":"2025","unstructured":"Walkey CJ, Snow KJ, Bulcha J, Cox AR, Martinez AE, Ljungberg MC, Lanza DG, De Giorgi M, Chuecos MA, Alves-Bezerra M, et al. A comprehensive atlas of AAV tropism in the mouse. Mol Ther. 2025;33:1282\u201399.","journal-title":"Mol Ther"},{"key":"4518_CR172","doi-asserted-by":"publisher","first-page":"e0517622","DOI":"10.1128\/spectrum.05176-22","volume":"11","author":"R Colon-Thillet","year":"2023","unstructured":"Colon-Thillet R, Stone D, Loprieno MA, Klouser L, Roychoudhury P, Santo TK, Xie H, Stensland L, Upham SL, Pepper G, et al. Liver-Humanized NSG-PiZ Mice Support the Study of Chronic Hepatitis B Virus Infection and Antiviral Therapies. Microbiol Spectr. 2023;11:e0517622.","journal-title":"Microbiol Spectr"},{"key":"4518_CR173","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41467-024-46194-y","volume":"15","author":"M Cabanes-Creus","year":"2024","unstructured":"Cabanes-Creus M, Liao SHY, Gale Navarro R, Knight M, Nazareth D, Lau NS, Ly M, Zhu E, Roca-Pinilla R, Bugallo Delgado R, et al. Harnessing whole human liver ex situ normothermic perfusion for preclinical AAV vector evaluation. Nat Commun. 2024;15:1876.","journal-title":"Nat Commun"},{"key":"4518_CR174","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1016\/j.ymthe.2024.05.005","volume":"32","author":"K Pekrun","year":"2024","unstructured":"Pekrun K, Stephens CJ, Gonzalez-Sandoval A, Goswami A, Zhang F, Tarantal AF, Blouse G, Kay MA. Correlation of antigen expression with epigenetic modifications after rAAV delivery of a human factor IX variant in mice and rhesus macaques. Mol Ther. 2024;32:2064\u201379.","journal-title":"Mol Ther"},{"key":"4518_CR175","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","volume":"32","author":"J Hordeaux","year":"2024","unstructured":"Hordeaux J, Lamontagne RJ, Song C, Buchlis G, Dyer C, Buza EL, Ramezani A, Wielechowski E, Greig JA, Chichester JA, et al. High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury. Mol Ther. 2024;32:952\u201368.","journal-title":"Mol Ther"},{"key":"4518_CR176","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1089\/hum.2021.116","volume":"33","author":"X Palazzi","year":"2022","unstructured":"Palazzi X, Pardo ID, Sirivelu MP, Newman L, Kumpf SW, Qian J, Franks T, Lopes S, Liu J, Monarski L, et al. Biodistribution and Tolerability of AAV-PHP.B-CBh-SMN1 in Wistar Han Rats and Cynomolgus Macaques Reveal Different Toxicologic Profiles. Hum Gene Ther. 2022;33:175\u201387.","journal-title":"Hum Gene Ther"},{"key":"4518_CR177","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3389\/fimmu.2017.01407","volume":"8","author":"A Ramesh","year":"2017","unstructured":"Ramesh A, Darko S, Hua A, Overman G, Ransier A, Francica JR, Trama A, Tomaras GD, Haynes BF, Douek DC, Kepler TB. Structure and Diversity of the Rhesus Macaque Immunoglobulin Loci through Multiple De Novo Genome Assemblies. Front Immunol. 2017;8:1407.","journal-title":"Front Immunol"},{"key":"4518_CR178","doi-asserted-by":"publisher","first-page":"818440","DOI":"10.3389\/fimmu.2022.818440","volume":"13","author":"M Kaduk","year":"2022","unstructured":"Kaduk M, Corcoran M, Karlsson Hedestam GB. Addressing IGHV Gene Structural Diversity Enhances Immunoglobulin Repertoire Analysis: Lessons From Rhesus Macaque. Front Immunol. 2022;13:818440.","journal-title":"Front Immunol"},{"key":"4518_CR179","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41577-018-0005-7","volume":"18","author":"JD Estes","year":"2018","unstructured":"Estes JD, Wong SW, Brenchley JM. Nonhuman primate models of human viral infections. Nat Rev Immunol. 2018;18:390\u2013404.","journal-title":"Nat Rev Immunol"},{"key":"4518_CR180","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1089\/ars.2010.3241","volume":"14","author":"I Messaoudi","year":"2011","unstructured":"Messaoudi I, Estep R, Robinson B, Wong SW. Nonhuman primate models of human immunology. Antioxid Redox Signal. 2011;14:261\u201373.","journal-title":"Antioxid Redox Signal"},{"key":"4518_CR181","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1016\/j.ymthe.2024.09.032","volume":"32","author":"HO Bazick","year":"2024","unstructured":"Bazick HO, Mao H, Niehaus JK, Wolter JM, Zylka MJ. AAV vector-derived elements integrate into Cas9-generated double-strand breaks and disrupt gene transcription. Mol Ther. 2024;32:4122\u201337.","journal-title":"Mol Ther"},{"key":"4518_CR182","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"4518_CR183","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1586\/ehm.11.48","volume":"4","author":"D Raj","year":"2011","unstructured":"Raj D, Davidoff AM, Nathwani AC. Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges. Expert Rev Hematol. 2011;4:539\u201349.","journal-title":"Expert Rev Hematol"},{"key":"4518_CR184","doi-asserted-by":"publisher","first-page":"1709095","DOI":"10.3389\/fmmed.2025.1709095","volume":"5","author":"N Kowshik","year":"2025","unstructured":"Kowshik N, Singh P. Advancing AAV vector manufacturing: challenges, innovations, and future directions for gene therapy. Front Mol Med. 2025;5:1709095.","journal-title":"Front Mol Med"},{"key":"4518_CR185","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1021\/acs.langmuir.2c02643","volume":"39","author":"CL Heldt","year":"2023","unstructured":"Heldt CL, Areo O, Joshi PU, Mi X, Ivanova Y, Berrill A. Empty and Full AAV Capsid Charge and Hydrophobicity Differences Measured with Single-Particle AFM. Langmuir. 2023;39:5641\u20138.","journal-title":"Langmuir"},{"key":"4518_CR186","doi-asserted-by":"publisher","first-page":"12817","DOI":"10.1021\/acs.analchem.1c02828","volume":"93","author":"L Strasser","year":"2021","unstructured":"Strasser L, Morgan TE, Guapo F, Fussl F, Forsey D, Anderson I, Bones J. A Native Mass Spectrometry-Based Assay for Rapid Assessment of the Empty:Full Capsid Ratio in Adeno-Associated Virus Gene Therapy Products. Anal Chem. 2021;93:12817\u201321.","journal-title":"Anal Chem"},{"key":"4518_CR187","doi-asserted-by":"publisher","first-page":"101607","DOI":"10.1016\/j.omtm.2025.101607","volume":"33","author":"LM Young","year":"2025","unstructured":"Young LM, Draper BE, Jarrold MF, Froelich CA, Motevalian SP. End-to-end characterization of AAV manufacturing process using charge detection mass spectrometry. Mol Ther Methods Clin Dev. 2025;33:101607.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR188","doi-asserted-by":"publisher","first-page":"14006","DOI":"10.1038\/mtm.2014.6","volume":"1","author":"DV Schaffer","year":"2014","unstructured":"Schaffer DV. AAV shuffles to the liver: commentary on Lisowski et al. Mol Ther Methods Clin Dev. 2014;1:14006.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR189","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fmicb.2011.00204","volume":"2","author":"M Bartel","year":"2011","unstructured":"Bartel M, Schaffer D, Buning H. Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity. Front Microbiol. 2011;2:204.","journal-title":"Front Microbiol"},{"key":"4518_CR190","doi-asserted-by":"publisher","first-page":"753467","DOI":"10.3389\/fimmu.2021.753467","volume":"12","author":"K Rapti","year":"2021","unstructured":"Rapti K, Grimm D. Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog. Front Immunol. 2021;12:753467.","journal-title":"Front Immunol"},{"key":"4518_CR191","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1128\/JVI.00254-08","volume":"82","author":"D Grimm","year":"2008","unstructured":"Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, Kay MA. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol. 2008;82:5887\u2013911.","journal-title":"J Virol"},{"key":"4518_CR192","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fimmu.2014.00009","volume":"5","author":"YS Tseng","year":"2014","unstructured":"Tseng YS, Agbandje-McKenna M. Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors. Front Immunol. 2014;5:9.","journal-title":"Front Immunol"},{"key":"4518_CR193","doi-asserted-by":"publisher","first-page":"857276","DOI":"10.3389\/fimmu.2022.857276","volume":"13","author":"DA Gross","year":"2022","unstructured":"Gross DA, Tedesco N, Leborgne C, Ronzitti G. Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients. Front Immunol. 2022;13:857276.","journal-title":"Front Immunol"},{"key":"4518_CR194","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.omtm.2023.08.016","volume":"30","author":"Y Kashiwakura","year":"2023","unstructured":"Kashiwakura Y, Endo K, Ugajin A, Kikuchi T, Hishikawa S, Nakamura H, Katakai Y, Baatartsogt N, Hiramoto T, Hayakawa M, et al. Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy. Mol Ther Methods Clin Dev. 2023;30:502\u201314.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR195","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.3390\/pharmaceutics17111492","volume":"17","author":"T Egorova","year":"2025","unstructured":"Egorova T, Starikova A, Polikarpova A. Emerging Technologies Tackling Adeno-Associated Viruses (AAV) Immunogenicity in Gene Therapy Applications. Pharmaceutics. 2025;17:1492.","journal-title":"Pharmaceutics"},{"key":"4518_CR196","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","volume":"25","author":"JR Mendell","year":"2022","unstructured":"Mendell JR, Connolly AM, Lehman KJ, Griffin DA, Khan SZ, Dharia SD, Quintana-Gallardo L, Rodino-Klapac LR. Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations. Mol Ther Methods Clin Dev. 2022;25:74\u201383.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR197","doi-asserted-by":"publisher","first-page":"e139881","DOI":"10.1172\/jci.insight.139881","volume":"5","author":"ZC Elmore","year":"2020","unstructured":"Elmore ZC, Oh DK, Simon KE, Fanous MM, Asokan A. Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. JCI Insight. 2020;5:e139881.","journal-title":"JCI Insight"},{"key":"4518_CR198","doi-asserted-by":"publisher","first-page":"e1375","DOI":"10.1002\/cti2.1375","volume":"11","author":"I Ros-Ganan","year":"2022","unstructured":"Ros-Ganan I, Hommel M, Trigueros-Motos L, Tamarit B, Rodriguez-Garcia E, Salas D, Perez G, Douar A, Combal JP, Benichou B, et al. Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies. Clin Transl Immunol. 2022;11:e1375.","journal-title":"Clin Transl Immunol"},{"key":"4518_CR199","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3390\/biom14070854","volume":"14","author":"N Chernyi","year":"2024","unstructured":"Chernyi N, Gavrilova D, Saruhanyan M, Oloruntimehin ES, Karabelsky A, Bezsonov E, Malogolovkin A. Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives. Biomolecules. 2024;14:854.","journal-title":"Biomolecules"},{"key":"4518_CR200","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365:2357\u201365.","journal-title":"N Engl J Med"},{"key":"4518_CR201","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1089\/1043034041648453","volume":"15","author":"YL Liu","year":"2004","unstructured":"Liu YL, Mingozzi F, Rodriguez-Colon SM, Joseph S, Dobrzynski E, Suzuki T, High KA, Herzog RW. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector. Hum Gene Ther. 2004;15:783\u201392.","journal-title":"Hum Gene Ther"},{"key":"4518_CR202","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/humc.2017.014","volume":"28","author":"JA Greig","year":"2017","unstructured":"Greig JA, Limberis MP, Bell P, Chen SJ, Calcedo R, Rader DJ, Wilson JM. Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR(+\/-) Rhesus Macaques. Hum Gene Ther Clin Dev. 2017;28:39\u201350.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"4518_CR203","doi-asserted-by":"publisher","first-page":"1580264","DOI":"10.3389\/fmed.2025.1580264","volume":"12","author":"W Yang","year":"2025","unstructured":"Yang W, Wang A, Liu B. Adeno-associated virus gene therapy for hemophilia: an update meta-analysis and systematic review. Front Med (Lausanne). 2025;12:1580264.","journal-title":"Front Med (Lausanne)"},{"key":"4518_CR204","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s13023-025-03893-z","volume":"20","author":"Q Zhao","year":"2025","unstructured":"Zhao Q, Peng H, Ma Y, Yuan H, Jiang H. In vivo applications and toxicities of AAV-based gene therapies in rare diseases. Orphanet J Rare Dis. 2025;20:368.","journal-title":"Orphanet J Rare Dis"},{"key":"4518_CR205","doi-asserted-by":"publisher","first-page":"12514","DOI":"10.3390\/ijms252312514","volume":"25","author":"Y van Chen","year":"2024","unstructured":"Chen Y, van Til NP, Bosma PJ. Gene Therapy for Inherited Liver Disease: To Add or to Edit. Int J Mol Sci. 2024;25:12514.","journal-title":"Int J Mol Sci"},{"key":"4518_CR206","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jtha.2023.11.010","volume":"22","author":"CW Coyle","year":"2024","unstructured":"Coyle CW, Knight KA, Brown HC, George SN, Denning G, Branella GM, Childers KC, Spiegel PC, Spencer HT, Doering CB. Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction. J Thromb Haemost. 2024;22:633\u201344.","journal-title":"J Thromb Haemost"},{"key":"4518_CR207","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1182\/bloodadvances.2021004742","volume":"5","author":"KA Knight","year":"2021","unstructured":"Knight KA, Coyle CW, Radford CE, Parker ET, Fedanov A, Shields JM, Szlam F, Purchel A, Chen M, Denning G, et al. Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction. Blood Adv. 2021;5:3333\u201343.","journal-title":"Blood Adv"},{"key":"4518_CR208","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11883-016-0579-0","volume":"18","author":"E Ajufo","year":"2016","unstructured":"Ajufo E, Cuchel M. Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia. Curr Atheroscler Rep. 2016;18:22.","journal-title":"Curr Atheroscler Rep"},{"key":"4518_CR209","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","volume":"141","author":"H Zhao","year":"2020","unstructured":"Zhao H, Li Y, He L, Pu W, Yu W, Li Y, Wu YT, Xu C, Wei Y, Ding Q, et al. In Vivo AAV-CRISPR\/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia. Circulation. 2020;141:67\u201379.","journal-title":"Circulation"},{"key":"4518_CR210","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jhep.2016.07.006","volume":"65","author":"N Brunetti-Pierri","year":"2016","unstructured":"Brunetti-Pierri N, Newsome PN. AAV-mediated liver-directed gene therapy for Acute Intermittent Porphyria: It is safe but is it effective? J Hepatol. 2016;65:666\u20137.","journal-title":"J Hepatol"},{"key":"4518_CR211","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/mt.2010.270","volume":"19","author":"E Salido","year":"2011","unstructured":"Salido E, Rodriguez-Pena M, Santana A, Beattie SG, Petry H, Torres A. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther. 2011;19:870\u20135.","journal-title":"Mol Ther"},{"key":"4518_CR212","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jhep.2015.09.014","volume":"64","author":"O Murillo","year":"2016","unstructured":"Murillo O, Luqui DM, Gazquez C, Martinez-Espartosa D, Navarro-Blasco I, Monreal JI, Guembe L, Moreno-Cermeno A, Corrales FJ, Prieto J, et al. Long-term metabolic correction of Wilson\u2019s disease in a murine model by gene therapy. J Hepatol. 2016;64:419\u201326.","journal-title":"J Hepatol"},{"key":"4518_CR213","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/jimd.12665","volume":"47","author":"RJ Chandler","year":"2024","unstructured":"Chandler RJ, Venditti CP. Gene therapy for organic acidemias: Lessons learned from methylmalonic and propionic acidemia. J Inherit Metab Dis. 2024;47:63\u201379.","journal-title":"J Inherit Metab Dis"},{"key":"4518_CR214","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.omtm.2023.06.008","volume":"30","author":"RJ Chandler","year":"2023","unstructured":"Chandler RJ, Di Pasquale G, Choi EY, Chang D, Smith SN, Sloan JL, Hoffmann V, Li L, Chiorini JA, Venditti CP. Systemic gene therapy using an AAV44.9 vector rescues a neonatal lethal mouse model of propionic acidemia. Mol Ther Methods Clin Dev. 2023;30:181\u201390.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR215","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jimd.12651","volume":"47","author":"M Martinez","year":"2024","unstructured":"Martinez M, Harding CO, Schwank G, Thony B. State-of-the-art 2023 on gene therapy for phenylketonuria. J Inherit Metab Dis. 2024;47:80\u201392.","journal-title":"J Inherit Metab Dis"},{"key":"4518_CR216","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1006\/mthe.2000.0065","volume":"1","author":"SJ Chen","year":"2000","unstructured":"Chen SJ, Tazelaar J, Moscioni AD, Wilson JM. In vivo selection of hepatocytes transduced with adeno-associated viral vectors. Mol Ther. 2000;1:414\u201322.","journal-title":"Mol Ther"},{"key":"4518_CR217","doi-asserted-by":"publisher","first-page":"100713","DOI":"10.1016\/j.jhepr.2023.100713","volume":"5","author":"ND Weber","year":"2023","unstructured":"Weber ND, Odriozola L, Ros-Ganan I, Garcia-Porrero G, Salas D, Argemi J, Combal JP, Kishimoto TK, Gonzalez-Aseguinolaza G. Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy. JHEP Rep. 2023;5:100713.","journal-title":"JHEP Rep"},{"key":"4518_CR218","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.ymthe.2006.01.014","volume":"13","author":"J Seppen","year":"2006","unstructured":"Seppen J, Bakker C, de Jong B, Kunne C, van den Oever K, Vandenberghe K, de Waart R, Twisk J, Bosma P. Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. Mol Ther. 2006;13:1085\u201392.","journal-title":"Mol Ther"},{"key":"4518_CR219","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/sj.gt.3302650","volume":"13","author":"A Ghosh","year":"2006","unstructured":"Ghosh A, Allamarvdasht M, Pan CJ, Sun MS, Mansfield BC, Byrne BJ, Chou JY. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Gene Ther. 2006;13:321\u20139.","journal-title":"Gene Ther"},{"key":"4518_CR220","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nbt.3469","volume":"34","author":"Y Yang","year":"2016","unstructured":"Yang Y, Wang L, Bell P, McMenamin D, He Z, White J, Yu H, Xu C, Morizono H, Musunuru K, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol. 2016;34:334\u20138.","journal-title":"Nat Biotechnol"},{"key":"4518_CR221","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jhep.2016.05.012","volume":"65","author":"D D\u2019Avola","year":"2016","unstructured":"D\u2019Avola D, Lopez-Franco E, Sangro B, Paneda A, Grossios N, Gil-Farina I, Benito A, Twisk J, Paz M, Ruiz J, et al. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol. 2016;65:776\u201383.","journal-title":"J Hepatol"},{"key":"4518_CR222","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.omtm.2019.12.014","volume":"19","author":"R Tao","year":"2020","unstructured":"Tao R, Xiao L, Zhou L, Zheng Z, Long J, Zhou L, Tang M, Dong B, Yao S. Long-Term Metabolic Correction of Phenylketonuria by AAV-Delivered Phenylalanine Amino Lyase. Mol Ther Methods Clin Dev. 2020;19:507\u201317.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR223","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.3390\/biomedicines11082227","volume":"11","author":"B Seker Yilmaz","year":"2023","unstructured":"Seker Yilmaz B, Gissen P. Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency. Biomedicines. 2023;11:2227.","journal-title":"Biomedicines"},{"key":"4518_CR224","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa2214084","volume":"389","author":"L D\u2019Antiga","year":"2023","unstructured":"D\u2019Antiga L, Beuers U, Ronzitti G, Brunetti-Pierri N, Baumann U, Di Giorgio A, Aronson S, Hubert A, Romano R, Junge N, et al. Gene Therapy in Patients with the Crigler-Najjar Syndrome. N Engl J Med. 2023;389:620\u201331.","journal-title":"N Engl J Med"},{"key":"4518_CR225","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtm.2021.04.017","volume":"22","author":"L Wang","year":"2021","unstructured":"Wang L, Muthuramu I, Somanathan S, Zhang H, Bell P, He Z, Yu H, Zhu Y, Tretiakova AP, Wilson JM. Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia. Mol Ther Methods Clin Dev. 2021;22:1\u201310.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR226","doi-asserted-by":"crossref","unstructured":"Kaittanis C, Teceno T, Knight A, Petibon Y, Sandoval P, Cohen L, Ahn SH, Belanger AP, Clark LM, Nguyen QD, et al. Longitudinal imaging of therapeutic enzyme expression after gene therapy for Fabry disease using positron emission tomography and the radiotracer [(18)F]AGAL. Mol Ther; 2024.","DOI":"10.1016\/j.ymthe.2024.11.021"},{"key":"4518_CR227","doi-asserted-by":"publisher","first-page":"100544","DOI":"10.1016\/j.medj.2024.10.021","volume":"6","author":"A Rossi","year":"2025","unstructured":"Rossi A, Romano R, Fecarotta S, Dell\u2019Anno M, Pecorella V, Passeggio R, Zancan S, Parenti G, Santamaria F, Borgia F, et al. Multi-year enzyme expression in patients with mucopolysaccharidosis type VI after liver-directed gene therapy. Med. 2025;6:100544.","journal-title":"Med"},{"key":"4518_CR228","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3390\/biomedicines10020302","volume":"10","author":"Z van Unnisa","year":"2022","unstructured":"Unnisa Z, Yoon JK, Schindler JW, Mason C, van Til NP. Gene Therapy Developments for Pompe Disease. Biomedicines. 2022;10:302.","journal-title":"Biomedicines"},{"key":"4518_CR229","doi-asserted-by":"publisher","first-page":"e10258","DOI":"10.1002\/btm2.10258","volume":"7","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Anselmo AC, Mitragotri S. Viral vector-based gene therapies in the clinic. Bioeng Transl Med. 2022;7:e10258.","journal-title":"Bioeng Transl Med"},{"key":"4518_CR230","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou SC, Ozelo MC, Kenet G, Peyvandi F, Wang M, Madan B, et al. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023;388:694\u2013705.","journal-title":"N Engl J Med"},{"key":"4518_CR231","doi-asserted-by":"publisher","first-page":"42110","DOI":"10.1021\/acsomega.5c01294","volume":"10","author":"P Qu","year":"2025","unstructured":"Qu P, Li X, Liu J, Su X, Han S, Wang Y, Luo Y, Li J, Ma C, Deng S, et al. Application of Gene Editing Technology Based on Targeted Delivery Materials in TNBC. ACS Omega. 2025;10:42110\u201326.","journal-title":"ACS Omega"},{"issue":"Suppl 1","key":"4518_CR232","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/jvh.13915","volume":"31","author":"A Kasimsetty","year":"2024","unstructured":"Kasimsetty A, Sabatino DE. Integration and the risk of liver cancer-Is there a real risk? J Viral Hepat. 2024;31(Suppl 1):26\u201334.","journal-title":"J Viral Hepat"},{"key":"4518_CR233","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.3748\/wjg.14.2303","volume":"14","author":"X Jin","year":"2008","unstructured":"Jin X, Yang YD, Li YM. Gene therapy: regulations, ethics and its practicalities in liver disease. World J Gastroenterol. 2008;14:2303\u20137.","journal-title":"World J Gastroenterol"},{"key":"4518_CR234","doi-asserted-by":"publisher","first-page":"E7379","DOI":"10.1073\/pnas.1802343115","volume":"115","author":"LJ Smith","year":"2018","unstructured":"Smith LJ, Wright J, Clark G, Ul-Hasan T, Jin X, Fong A, Chandra M, St Martin T, Rubin H, Knowlton D, et al. Stem cell-derived clade F AAVs mediate high-efficiency homologous recombination-based genome editing. Proc Natl Acad Sci U S A. 2018;115:E7379\u201388.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4518_CR235","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1089\/hum.2020.049","volume":"31","author":"S Chatterjee","year":"2020","unstructured":"Chatterjee S, Sivanandam V, Wong Kk J. Adeno-Associated Virus and Hematopoietic Stem Cells: The Potential of Adeno-Associated Virus Hematopoietic Stem Cells in Genetic Medicines. Hum Gene Ther. 2020;31:542\u201352.","journal-title":"Hum Gene Ther"},{"key":"4518_CR236","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.omtm.2020.03.009","volume":"17","author":"SS Ahmed","year":"2020","unstructured":"Ahmed SS, Rubin H, Wang M, Faulkner D, Sengooba A, Dollive SN, Avila N, Ellsworth JL, Lamppu D, Lobikin M, et al. Sustained Correction of a Murine Model of Phenylketonuria following a Single Intravenous Administration of AAVHSC15-PAH. Mol Ther Methods Clin Dev. 2020;17:568\u201380.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR237","doi-asserted-by":"publisher","first-page":"100065","DOI":"10.1016\/j.jhepr.2019.100065","volume":"2","author":"SL Ginn","year":"2020","unstructured":"Ginn SL, Amaya AK, Liao SHY, Zhu E, Cunningham SC, Lee M, Hallwirth CV, Logan GJ, Tay SS, Cesare AJ, et al. Efficient in vivo editing of OTC-deficient patient-derived primary human hepatocytes. JHEP Rep. 2020;2:100065.","journal-title":"JHEP Rep"},{"key":"4518_CR238","doi-asserted-by":"publisher","first-page":"6461","DOI":"10.3390\/ijms21186461","volume":"21","author":"H Yang","year":"2020","unstructured":"Yang H, Ren S, Yu S, Pan H, Li T, Ge S, Zhang J, Xia N. Methods Favoring Homology-Directed Repair Choice in Response to CRISPR\/Cas9 Induced-Double Strand Breaks. Int J Mol Sci. 2020;21:6461.","journal-title":"Int J Mol Sci"},{"key":"4518_CR239","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.jhep.2025.06.018","volume":"83","author":"M Milani","year":"2025","unstructured":"Milani M, Starinieri F, Beretta S, Monti M, Canepari C, Marabotti F, Zambrano S, Mazza D, Fabiano A, Simoni C, et al. Spatiotemporal liver dynamics shape hepatocellular heterogeneity and impact in vivo gene engineering. J Hepatol. 2025;83:1392\u2013409.","journal-title":"J Hepatol"},{"key":"4518_CR240","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3390\/biom12070915","volume":"12","author":"H Sawada","year":"2022","unstructured":"Sawada H, Daugherty A, Lu HS. Expression of a PCSK9 Gain-of-Function Mutation in C57BL\/6J Mice to Facilitate Angiotensin II-Induced AAAs. Biomolecules. 2022;12:915.","journal-title":"Biomolecules"},{"key":"4518_CR241","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s44321-023-00008-8","volume":"16","author":"L Torella","year":"2024","unstructured":"Torella L, Klermund J, Bilbao-Arribas M, Tamayo I, Andrieux G, Chmielewski KO, Vales A, Olague C, Moreno-Luqui D, Raimondi I, et al. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1. EMBO Mol Med. 2024;16:112\u201331.","journal-title":"EMBO Mol Med"},{"key":"4518_CR242","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1165\/rcmb.2019-0006OC","volume":"61","author":"AL Cooney","year":"2019","unstructured":"Cooney AL, Thornell IM, Singh BK, Shah VS, Stoltz DA, McCray PB Jr., Zabner J, Sinn PL. A Novel AAV-mediated Gene Delivery System Corrects CFTR Function in Pigs. Am J Respir Cell Mol Biol. 2019;61:747\u201354.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"4518_CR243","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/mt.2014.254","volume":"23","author":"AL Cooney","year":"2015","unstructured":"Cooney AL, Singh BK, Sinn PL. Hybrid nonviral\/viral vector systems for improved piggyBac DNA transposon in vivo delivery. Mol Ther. 2015;23:667\u201374.","journal-title":"Mol Ther"},{"key":"4518_CR244","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/hep.30773","volume":"70","author":"SM Siew","year":"2019","unstructured":"Siew SM, Cunningham SC, Zhu E, Tay SS, Venuti E, Bolitho C, Alexander IE. Prevention of Cholestatic Liver Disease and Reduced Tumorigenicity in a Murine Model of PFIC Type 3 Using Hybrid AAV-piggyBac Gene Therapy. Hepatology. 2019;70:2047\u201361.","journal-title":"Hepatology"},{"key":"4518_CR245","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.3390\/cells9102227","volume":"9","author":"QT La","year":"2020","unstructured":"La QT, Ren B, Logan GJ, Cunningham SC, Khandekar N, Nassif NT, O\u2019Brien BA, Alexander IE, Simpson AM. Use of a Hybrid Adeno-Associated Viral Vector Transposon System to Deliver the Insulin Gene to Diabetic NOD Mice. Cells. 2020;9:2227.","journal-title":"Cells"},{"key":"4518_CR246","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-018-0209-1","volume":"24","author":"L Villiger","year":"2018","unstructured":"Villiger L, Grisch-Chan HM, Lindsay H, Ringnalda F, Pogliano CB, Allegri G, Fingerhut R, Haberle J, Matos J, Robinson MD, et al. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Nat Med. 2018;24:1519\u201325.","journal-title":"Nat Med"},{"key":"4518_CR247","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41551-020-00671-z","volume":"5","author":"L Villiger","year":"2021","unstructured":"Villiger L, Rothgangl T, Witzigmann D, Oka R, Lin PJC, Qi W, Janjuha S, Berk C, Ringnalda F, Beattie MB, et al. In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA. Nat Biomed Eng. 2021;5:179\u201389.","journal-title":"Nat Biomed Eng"},{"key":"4518_CR248","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","volume":"39","author":"T Rothgangl","year":"2021","unstructured":"Rothgangl T, Dennis MK, Lin PJC, Oka R, Witzigmann D, Villiger L, Qi W, Hruzova M, Kissling L, Lenggenhager D, et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat Biotechnol. 2021;39:949\u201357.","journal-title":"Nat Biotechnol"},{"key":"4518_CR249","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, Wang K, Iyer S, Dutta C, Clendaniel V, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593:429\u201334.","journal-title":"Nature"},{"key":"4518_CR250","doi-asserted-by":"publisher","first-page":"eabl9238","DOI":"10.1126\/scitranslmed.abl9238","volume":"14","author":"D Bock","year":"2022","unstructured":"Bock D, Rothgangl T, Villiger L, Schmidheini L, Matsushita M, Mathis N, Ioannidi E, Rimann N, Grisch-Chan HM, Kreutzer S, et al. In vivo prime editing of a metabolic liver disease in mice. Sci Transl Med. 2022;14:eabl9238.","journal-title":"Sci Transl Med"},{"key":"4518_CR251","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41587-024-02523-6","volume":"43","author":"JJ Kim","year":"2025","unstructured":"Kim JJ, Kurial SNT, Choksi PK, Nunez M, Lunow-Luke T, Bartel J, Driscoll J, Her CL, Dhillon S, Yue W, et al. AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion. Nat Biotechnol. 2025;43:1966\u201378.","journal-title":"Nat Biotechnol"},{"key":"4518_CR252","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1016\/j.ymthe.2025.04.027","volume":"33","author":"J Becker","year":"2025","unstructured":"Becker J, Domenger C, Choksi P, Kramer C, Baumgartl C, Maiakovska O, Kim JJ, Weinmann J, Huber G, Schmidt F, et al. Identification of a robust promoter in mouse and human hepatocytes by in vivo biopanning of a barcoded AAV library. Mol Ther. 2025;33:3881\u2013901.","journal-title":"Mol Ther"},{"key":"4518_CR253","doi-asserted-by":"publisher","first-page":"105834","DOI":"10.1016\/j.ebiom.2025.105834","volume":"118","author":"G Geng","year":"2025","unstructured":"Geng G, Xu Y, Hu Z, Wang H, Chen X, Yuan W, Shu Y. Viral and non-viral vectors in gene therapy: current state and clinical perspectives. EBioMedicine. 2025;118:105834.","journal-title":"EBioMedicine"},{"key":"4518_CR254","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/sj.mt.6300060","volume":"15","author":"AH Chang","year":"2007","unstructured":"Chang AH, Sadelain M. The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. Mol Ther. 2007;15:445\u201356.","journal-title":"Mol Ther"},{"key":"4518_CR255","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1089\/scd.2007.0015","volume":"16","author":"MA Harkey","year":"2007","unstructured":"Harkey MA, Kaul R, Jacobs MA, Kurre P, Bovee D, Levy R, Blau CA. Multiarm high-throughput integration site detection: limitations of LAM-PCR technology and optimization for clonal analysis. Stem Cells Dev. 2007;16:381\u201392.","journal-title":"Stem Cells Dev"},{"key":"4518_CR256","doi-asserted-by":"publisher","first-page":"1708724","DOI":"10.3389\/fbioe.2025.1708724","volume":"13","author":"K Kochergin-Nikitsky","year":"2025","unstructured":"Kochergin-Nikitsky K, Lavrov A, Smirnikhina S. Methodological landscape in the field of integration site identification of retroviruses and retroviral vectors. Front Bioeng Biotechnol. 2025;13:1708724.","journal-title":"Front Bioeng Biotechnol"},{"key":"4518_CR257","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/hep.26204","volume":"58","author":"I Rittelmeyer","year":"2013","unstructured":"Rittelmeyer I, Rothe M, Brugman MH, Iken M, Schambach A, Manns MP, Baum C, Modlich U, Ott M. Hepatic lentiviral gene transfer is associated with clonal selection, but not with tumor formation in serially transplanted rodents. Hepatology. 2013;58:397\u2013408.","journal-title":"Hepatology"},{"key":"4518_CR258","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","volume":"30","author":"A Pupo","year":"2022","unstructured":"Pupo A, Fernandez A, Low SH, Francois A, Suarez-Amaran L, Samulski RJ. AAV vectors: The Rubik\u2019s cube of human gene therapy. Mol Ther. 2022;30:3515\u201341.","journal-title":"Mol Ther"},{"key":"4518_CR259","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/hep.31570","volume":"73","author":"RJ Chandler","year":"2021","unstructured":"Chandler RJ, Venturoni LE, Liao J, Hubbard BT, Schneller JL, Hoffmann V, Gordo S, Zang S, Ko CW, Chau N, et al. Promoterless, Nuclease-Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia. Hepatology. 2021;73:2223\u201337.","journal-title":"Hepatology"},{"key":"4518_CR260","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1016\/j.ymthe.2024.09.035","volume":"32","author":"F Puzzo","year":"2024","unstructured":"Puzzo F, Crossley MP, Goswami A, Zhang F, Pekrun K, Garzon JL, Cimprich KA, Kay MA. AAV-mediated genome editing is influenced by the formation of R-loops. Mol Ther. 2024;32:4256\u201371.","journal-title":"Mol Ther"},{"key":"4518_CR261","doi-asserted-by":"crossref","unstructured":"Bedoyan JK, Morgan T, Sun A, Li H, Gruskin D, Payton M, Chereau F, Swenson ES, Lin Q, Kay MA, Vockley J. First-in-human nuclease-free homologous recombination-dependent gene editing in pediatric patients with methylmalonic acidemia: results of a phase 1\/2 study. Gene Ther 2026.","DOI":"10.1038\/s41434-026-00609-1"},{"key":"4518_CR262","doi-asserted-by":"publisher","first-page":"101619","DOI":"10.1016\/j.xcrm.2024.101619","volume":"5","author":"F Esposito","year":"2024","unstructured":"Esposito F, Dell\u2019Aquila F, Rhiel M, Auricchio S, Chmielewski KO, Andrieux G, Ferla R, Horrach PS, Padmanabhan A, Di Cunto R, et al. Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases. Cell Rep Med. 2024;5:101619.","journal-title":"Cell Rep Med"},{"key":"4518_CR263","first-page":"617","volume":"11","author":"JH Park","year":"2024","unstructured":"Park JH, Kwon S, Choi SY, Kim B, Oh J. Optimizing the Amino Acid Sequence Enhances the Productivity and Bioefficacy of the RBP-Albumin Fusion Protein. Bioeng (Basel). 2024;11:617.","journal-title":"Bioeng (Basel)"},{"key":"4518_CR264","doi-asserted-by":"crossref","unstructured":"Tornabene P, Ferla R, Llado-Santaeularia M, Centrulo M, Dell\u2019Anno M, Esposito F, Marrocco E, Pone E, Minopoli R, Iodice C et al. Therapeutic homology-independent targeted integration in retina and liver. Nat Commun 2022, 13:1963.","DOI":"10.1038\/s41467-022-29550-8"},{"key":"4518_CR265","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.stem.2024.04.022","volume":"31","author":"K Zhang","year":"2024","unstructured":"Zhang K, Wan P, Wang L, Wang Z, Tan F, Li J, Ma X, Cen J, Yuan X, Liu Y, et al. Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases. Cell Stem Cell. 2024;31:1187\u2013e12021188.","journal-title":"Cell Stem Cell"},{"key":"4518_CR266","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.molmed.2022.10.001","volume":"29","author":"KM MacNeil","year":"2023","unstructured":"MacNeil KM, Dodge MJ, Evans AM, Tessier TM, Weinberg JB, Mymryk JS. Adenoviruses in medicine: innocuous pathogen, predator, or partner. Trends Mol Med. 2023;29:4\u201319.","journal-title":"Trends Mol Med"},{"key":"4518_CR267","doi-asserted-by":"publisher","first-page":"e0083622","DOI":"10.1128\/jcm.00836-22","volume":"62","author":"AE Kajon","year":"2024","unstructured":"Kajon AE. Adenovirus infections: new insights for the clinical laboratory. J Clin Microbiol. 2024;62:e0083622.","journal-title":"J Clin Microbiol"},{"key":"4518_CR268","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/TP.0000000000003988","volume":"106","author":"OM Al-Heeti","year":"2022","unstructured":"Al-Heeti OM, Cathro HP, Ison MG. Adenovirus Infection and Transplantation. Transplantation. 2022;106:920\u20137.","journal-title":"Transplantation"},{"key":"4518_CR269","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","volume":"132","author":"SN Waddington","year":"2008","unstructured":"Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008;132:397\u2013409.","journal-title":"Cell"},{"key":"4518_CR270","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","volume":"13","author":"WS Wold","year":"2013","unstructured":"Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013;13:421\u201333.","journal-title":"Curr Gene Ther"},{"key":"4518_CR271","doi-asserted-by":"publisher","first-page":"199","DOI":"10.5114\/ceh.2020.99512","volume":"6","author":"SF Ghahestani","year":"2020","unstructured":"Ghahestani SF, Shiri A, Moattari A, Sarvari J, Tamaddon AM, Hossein SY. The superior role of coagulation factor FX over FVII in adenoviral-mediated innate immune induction of the hepatocyte: an in vitro experiment. Clin Exp Hepatol. 2020;6:199\u2013206.","journal-title":"Clin Exp Hepatol"},{"key":"4518_CR272","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/mt.2013.100","volume":"21","author":"AH Baker","year":"2013","unstructured":"Baker AH, Nicklin SA, Shayakhmetov DM. FX and host defense evasion tactics by adenovirus. Mol Ther. 2013;21:1109\u201311.","journal-title":"Mol Ther"},{"key":"4518_CR273","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1128\/JVI.05760-11","volume":"86","author":"R Khare","year":"2012","unstructured":"Khare R, Reddy VS, Nemerow GR, Barry MA. Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. J Virol. 2012;86:2293\u2013301.","journal-title":"J Virol"},{"key":"4518_CR274","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, Wang T, Yan F, Yang S, Xia X. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023;8:149.","journal-title":"Signal Transduct Target Ther"},{"key":"4518_CR275","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.biotechadv.2008.10.003","volume":"27","author":"E Dormond","year":"2009","unstructured":"Dormond E, Perrier M, Kamen A. From the first to the third generation adenoviral vector: what parameters are governing the production yield? Biotechnol Adv. 2009;27:133\u201344.","journal-title":"Biotechnol Adv"},{"key":"4518_CR276","doi-asserted-by":"publisher","first-page":"911429","DOI":"10.3389\/fgene.2022.911429","volume":"13","author":"ZF Li","year":"2022","unstructured":"Li ZF, Wu NQ. The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy. Front Genet. 2022;13:911429.","journal-title":"Front Genet"},{"key":"4518_CR277","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1089\/hum.2010.167","volume":"22","author":"D Dimmock","year":"2011","unstructured":"Dimmock D, Brunetti-Pierri N, Palmer DJ, Beaudet AL, Ng P. Correction of hyperbilirubinemia in gunn rats using clinically relevant low doses of helper-dependent adenoviral vectors. Hum Gene Ther. 2011;22:483\u20138.","journal-title":"Hum Gene Ther"},{"key":"4518_CR278","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/gt.2015.107","volume":"23","author":"R Castello","year":"2016","unstructured":"Castello R, Borzone R, D\u2019Aria S, Annunziata P, Piccolo P, Brunetti-Pierri N. Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1. Gene Ther. 2016;23:129\u201334.","journal-title":"Gene Ther"},{"key":"4518_CR279","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/sj.mt.6300188","volume":"15","author":"DD Koeberl","year":"2007","unstructured":"Koeberl DD, Sun B, Bird A, Chen YT, Oka K, Chan L. Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia. Mol Ther. 2007;15:1253\u20138.","journal-title":"Mol Ther"},{"key":"4518_CR280","first-page":"001","volume":"Suppl 5","author":"A Rosewell","year":"2011","unstructured":"Rosewell A, Vetrini F, Ng P. Helper-Dependent Adenoviral Vectors. J Genet Syndr Gene Ther. 2011;Suppl 5:001.","journal-title":"J Genet Syndr Gene Ther"},{"key":"4518_CR281","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/89349","volume":"19","author":"P Umana","year":"2001","unstructured":"Umana P, Gerdes CA, Stone D, Davis JR, Ward D, Castro MG, Lowenstein PR. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol. 2001;19:582\u20135.","journal-title":"Nat Biotechnol"},{"key":"4518_CR282","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-1-59745-237-3_3","volume":"433","author":"DJ Palmer","year":"2008","unstructured":"Palmer DJ, Ng P. Methods for the production of helper-dependent adenoviral vectors. Methods Mol Biol. 2008;433:33\u201353.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"4518_CR283","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.3390\/ijms22052417","volume":"22","author":"F Kreppel","year":"2021","unstructured":"Kreppel F, Hagedorn C. Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. Int J Mol Sci. 2021;22(5):2417.","journal-title":"Int J Mol Sci"},{"key":"4518_CR284","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.molcel.2016.03.029","volume":"62","author":"PJ Thompson","year":"2016","unstructured":"Thompson PJ, Macfarlan TS, Lorincz MC. Long Terminal Repeats: From Parasitic Elements to Building Blocks of the Transcriptional Regulatory Repertoire. Mol Cell. 2016;62:766\u201376.","journal-title":"Mol Cell"},{"key":"4518_CR285","doi-asserted-by":"publisher","first-page":"10889","DOI":"10.1128\/JVI.77.20.10889-10899.2003","volume":"77","author":"JP McGettigan","year":"2003","unstructured":"McGettigan JP, Naper K, Orenstein J, Koser M, McKenna PM, Schnell MJ. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J Virol. 2003;77:10889\u201399.","journal-title":"J Virol"},{"key":"4518_CR286","doi-asserted-by":"publisher","first-page":"e0030824","DOI":"10.1128\/jvi.00308-24","volume":"98","author":"J Twentyman","year":"2024","unstructured":"Twentyman J, Emerman M, Ohainle M. Capsid-dependent lentiviral restrictions. J Virol. 2024;98:e0030824.","journal-title":"J Virol"},{"key":"4518_CR287","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.tips.2022.01.001","volume":"43","author":"M Herrera-Barrera","year":"2022","unstructured":"Herrera-Barrera M, Sahay G. Mining LTR-retrotransposon genes for mRNA delivery. Trends Pharmacol Sci. 2022;43:355\u20137.","journal-title":"Trends Pharmacol Sci"},{"key":"4518_CR288","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.virol.2005.09.012","volume":"344","author":"M Yamashita","year":"2006","unstructured":"Yamashita M, Emerman M. Retroviral infection of non-dividing cells: old and new perspectives. Virology. 2006;344:88\u201393.","journal-title":"Virology"},{"key":"4518_CR289","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/v12091016","volume":"12","author":"A Gutierrez-Guerrero","year":"2020","unstructured":"Gutierrez-Guerrero A, Cosset FL, Verhoeyen E. Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy. Viruses. 2020;12:1016.","journal-title":"Viruses"},{"key":"4518_CR290","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJMoa2400442","volume":"391","author":"F Eichler","year":"2024","unstructured":"Eichler F, Duncan CN, Musolino PL, Lund TC, Gupta AO, De Oliveira S, Thrasher AJ, Aubourg P, Kuhl JS, Loes DJ, et al. Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2024;391:1302\u201312.","journal-title":"N Engl J Med"},{"key":"4518_CR291","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","volume":"391","author":"CN Duncan","year":"2024","unstructured":"Duncan CN, Bledsoe JR, Grzywacz B, Beckman A, Bonner M, Eichler FS, Kuhl JS, Harris MH, Slauson S, Colvin RA, et al. Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2024;391:1287\u2013301.","journal-title":"N Engl J Med"},{"key":"4518_CR292","doi-asserted-by":"publisher","first-page":"eaav7325","DOI":"10.1126\/scitranslmed.aav7325","volume":"11","author":"M Milani","year":"2019","unstructured":"Milani M, Annoni A, Moalli F, Liu T, Cesana D, Calabria A, Bartolaccini S, Biffi M, Russo F, Visigalli I, et al. Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Sci Transl Med. 2019;11:eaav7325.","journal-title":"Sci Transl Med"},{"key":"4518_CR293","first-page":"1153","volume":"12","author":"V Geraldes","year":"2023","unstructured":"Geraldes V, Laranjo S, Nunes C, Rocha I. Central Autonomic Network Regions and Hypertension: Unveiling Sympathetic Activation and Genetic Therapeutic Perspectives. Biology (Basel). 2023;12:1153.","journal-title":"Biology (Basel)"},{"key":"4518_CR294","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/TP.0b013e31819ca245","volume":"87","author":"J Birraux","year":"2009","unstructured":"Birraux J, Menzel O, Wildhaber B, Jond C, Nguyen TH, Chardot C. A step toward liver gene therapy: efficient correction of the genetic defect of hepatocytes isolated from a patient with Crigler-Najjar syndrome type 1 with lentiviral vectors. Transplantation. 2009;87:1006\u201312.","journal-title":"Transplantation"},{"key":"4518_CR295","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1038\/s41467-022-30102-3","volume":"13","author":"M Milani","year":"2022","unstructured":"Milani M, Canepari C, Liu T, Biffi M, Russo F, Plati T, Curto R, Patarroyo-White S, Drager D, Visigalli I, et al. Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates. Nat Commun. 2022;13:2454.","journal-title":"Nat Commun"},{"key":"4518_CR296","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1038\/s41467-025-60073-0","volume":"16","author":"C Canepari","year":"2025","unstructured":"Canepari C, Milani M, Simoni C, Starinieri F, Volpin M, Fabiano A, Biffi M, Russo F, Norata R, Rocchi M, et al. Enhancing the potency of in vivo lentiviral vector mediated gene therapy to hepatocytes. Nat Commun. 2025;16:4802.","journal-title":"Nat Commun"},{"key":"4518_CR297","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1038\/s41467-022-32576-7","volume":"13","author":"CT Nicolas","year":"2022","unstructured":"Nicolas CT, VanLith CJ, Hickey RD, Du Z, Hillin LG, Guthman RM, Cao WJ, Haugo B, Lillegard A, Roy D, et al. In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions. Nat Commun. 2022;13:5012.","journal-title":"Nat Commun"},{"key":"4518_CR298","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41434-025-00536-7","volume":"32","author":"I von Filz","year":"2025","unstructured":"von Filz I, Mojoudi M, Bento R, Taggart MS, Dinicu AT, Wojtkiewicz G, Coert JH, van der Mink AB, Weissleder R, Parekkadan B, Uygun K. Ex vivo machine perfusion as a platform for lentiviral gene delivery in rat livers. Gene Ther. 2025;32:421\u20139.","journal-title":"Gene Ther"},{"key":"4518_CR299","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1080\/14760584.2021.1988854","volume":"20","author":"MW Ku","year":"2021","unstructured":"Ku MW, Charneau P, Majlessi L. Use of lentiviral vectors in vaccination. Expert Rev Vaccines. 2021;20:1571\u201386.","journal-title":"Expert Rev Vaccines"},{"key":"4518_CR300","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone MC, O\u2019Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32:1529\u201341.","journal-title":"Leukemia"},{"key":"4518_CR301","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1093\/nar\/gkv202","volume":"43","author":"Y Zheng","year":"2015","unstructured":"Zheng Y, Yu F, Wu Y, Si L, Xu H, Zhang C, Xia Q, Xiao S, Wang Q, He Q, et al. Broadening the versatility of lentiviral vectors as a tool in nucleic acid research via genetic code expansion. Nucleic Acids Res. 2015;43:e73.","journal-title":"Nucleic Acids Res"},{"key":"4518_CR302","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1089\/hum.2013.111","volume":"25","author":"ES Wong","year":"2014","unstructured":"Wong ES, McIntyre C, Peters HL, Ranieri E, Anson DS, Fletcher JM. Correction of methylmalonic aciduria in vivo using a codon-optimized lentiviral vector. Hum Gene Ther. 2014;25:529\u201338.","journal-title":"Hum Gene Ther"},{"key":"4518_CR303","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1093\/hmg\/ddu746","volume":"24","author":"J Clar","year":"2015","unstructured":"Clar J, Mutel E, Gri B, Creneguy A, Stefanutti A, Gaillard S, Ferry N, Beuf O, Mithieux G, Nguyen TH, Rajas F. Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice. Hum Mol Genet. 2015;24:2287\u201396.","journal-title":"Hum Mol Genet"},{"key":"4518_CR304","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1006\/mthe.2001.0330","volume":"3","author":"MA Schnell","year":"2001","unstructured":"Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R, Chen SJ, Varnavski AN, LeClair C, Raper SE, Wilson JM. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther. 2001;3:708\u201322.","journal-title":"Mol Ther"},{"key":"4518_CR305","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/10611860601141481","volume":"15","author":"JE Adrian","year":"2007","unstructured":"Adrian JE, Kamps JA, Poelstra K, Scherphof GL, Meijer DK, Kaneda Y. Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelopes fused with targeted liposomes. J Drug Target. 2007;15:75\u201382.","journal-title":"J Drug Target"},{"key":"4518_CR306","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s44321-024-00072-8","volume":"16","author":"M Milani","year":"2024","unstructured":"Milani M, Canepari C, Assanelli S, Merlin S, Borroni E, Starinieri F, Biffi M, Russo F, Fabiano A, Zambroni D, et al. GP64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia A mice. EMBO Mol Med. 2024;16:1427\u201350.","journal-title":"EMBO Mol Med"},{"key":"4518_CR307","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2165\/00019053-200321100-00002","volume":"21","author":"JP Galanaud","year":"2003","unstructured":"Galanaud JP, Pelletier-Fleury N, Logerot-Lebrun H, Lambert T. Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated factor VII. PharmacoEconomics. 2003;21:699\u2013707.","journal-title":"PharmacoEconomics"},{"key":"4518_CR308","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ymthe.2017.03.033","volume":"25","author":"AW Nienhuis","year":"2017","unstructured":"Nienhuis AW, Nathwani AC, Davidoff AM. Gene Therapy for Hemophilia. Mol Ther. 2017;25:1163\u20137.","journal-title":"Mol Ther"},{"key":"4518_CR309","doi-asserted-by":"publisher","first-page":"e22552","DOI":"10.1002\/adma.202522552","volume":"38","author":"Q Wang","year":"2026","unstructured":"Wang Q, Lin Y, Xiao J, Xu K, Luo Z, Ren H, Liu F, Jia L, Wei T, Cheng Q. Optimizing Peptide Ionizable Lipids Enables Efficient and Low-Toxicity mRNA Delivery for In Vivo Prime Editing and Protein Replacement Therapy. Adv Mater. 2026;38:e22552.","journal-title":"Adv Mater"},{"key":"4518_CR310","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1002\/hep.22195","volume":"47","author":"KJ Wangensteen","year":"2008","unstructured":"Wangensteen KJ, Wilber A, Keng VW, He Z, Matise I, Wangensteen L, Carson CM, Chen Y, Steer CJ, McIvor RS, et al. A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver. Hepatology. 2008;47:1714\u201324.","journal-title":"Hepatology"},{"key":"4518_CR311","first-page":"106","volume":"13","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Liu Q, Deng Z, Liu J, Li S, Hong M, Peng Y. Evaluating the Metabolic Basis of alpha-Gal A mRNA Therapy for Fabry Disease. Biology (Basel). 2024;13:106.","journal-title":"Biology (Basel)"},{"key":"4518_CR312","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2147\/DDDT.S281631","volume":"16","author":"CN Majeed","year":"2022","unstructured":"Majeed CN, Ma CD, Xiao T, Rudnick S, Bonkovsky HL. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. Drug Des Devel Ther. 2022;16:1827\u201345.","journal-title":"Drug Des Devel Ther"},{"key":"4518_CR313","doi-asserted-by":"publisher","first-page":"11915","DOI":"10.1073\/pnas.0805434105","volume":"105","author":"M Frank-Kamenetsky","year":"2008","unstructured":"Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A. 2008;105:11915\u201320.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4518_CR314","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, Gonzalez-Duarte A, et al. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023;389:1553\u201365.","journal-title":"N Engl J Med"},{"key":"4518_CR315","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/s41551-025-01399-4","volume":"9","author":"T Rothgangl","year":"2025","unstructured":"Rothgangl T, Talas A, Ioannidi EI, Weber Y, Bock D, Matsushita M, Villiger EA, Schmidheini L, Moon WJ, Lin PJC, et al. Treatment of a metabolic liver disease in mice with a transient prime editing approach. Nat Biomed Eng. 2025;9:1705\u201318.","journal-title":"Nat Biomed Eng"},{"key":"4518_CR316","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.ymthe.2020.11.023","volume":"29","author":"N Li","year":"2021","unstructured":"Li N, Gou S, Wang J, Zhang Q, Huang X, Xie J, Li L, Jin Q, Ouyang Z, Chen F, et al. CRISPR\/Cas9-Mediated Gene Correction in Newborn Rabbits with Hereditary Tyrosinemia Type I. Mol Ther. 2021;29:1001\u201315.","journal-title":"Mol Ther"},{"key":"4518_CR317","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40265-021-01529-7","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Correction to: Inclisiran: First Approval. Drugs. 2021;81:1129.","journal-title":"Drugs"},{"key":"4518_CR318","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","volume":"83","author":"J Armisen","year":"2025","unstructured":"Armisen J, Rauschecker M, Sarv J, Liljeblad M, Wernevik L, Niazi M, Knochel J, Eklund O, Sandell T, Sherwood J, et al. AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148\u00a0M homozygous participants: Two randomized phase I trials. J Hepatol. 2025;83:31\u201342.","journal-title":"J Hepatol"},{"key":"4518_CR319","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jhep.2021.09.021","volume":"76","author":"J Hsieh","year":"2022","unstructured":"Hsieh J, Molusky MM, McCabe KM, Fotakis P, Xiao T, Tascau L, Zeana-Schliep L, DaSilva-Jardine P, Tall AR. TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion. J Hepatol. 2022;76:383\u201393.","journal-title":"J Hepatol"},{"key":"4518_CR320","doi-asserted-by":"publisher","first-page":"100514","DOI":"10.1016\/j.jlr.2024.100514","volume":"65","author":"Y Ma","year":"2024","unstructured":"Ma Y, Cai H, Smith J, Chu CH, Mercer SE, Boehm S, McDonald I, Zinker B, Cheng D. Evaluation of antisense oligonucleotide therapy targeting Hsd17b13 in a fibrosis mice model. J Lipid Res. 2024;65:100514.","journal-title":"J Lipid Res"},{"key":"4518_CR321","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1038\/s41467-022-33493-5","volume":"13","author":"C Ge","year":"2022","unstructured":"Ge C, Tan J, Dai X, Kuang Q, Zhong S, Lai L, Yi C, Sun Y, Luo J, Zhang C, et al. Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK. Nat Commun. 2022;13:5945.","journal-title":"Nat Commun"},{"key":"4518_CR322","doi-asserted-by":"publisher","first-page":"156054","DOI":"10.1016\/j.metabol.2024.156054","volume":"162","author":"C Shen","year":"2025","unstructured":"Shen C, Pan Z, Xie W, Zhao J, Miao D, Zhao L, Liu M, Zhong Y, Zhong C, Gonzalez FJ, et al. Hepatocyte-specific SLC27A4 deletion ameliorates nonalcoholic fatty liver disease in mice via suppression of phosphatidylcholine-mediated PXR activation. Metabolism. 2025;162:156054.","journal-title":"Metabolism"},{"key":"4518_CR323","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/hae.14907","volume":"30","author":"C Ay","year":"2024","unstructured":"Ay C, Frenzel L, Pinachyan K, Le Quellec S. Gene therapy for haemophilia A and B, from basic principles to clinical implementation: An illustrated review. Haemophilia. 2024;30:5\u201315.","journal-title":"Haemophilia"},{"key":"4518_CR324","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.omtm.2020.11.005","volume":"20","author":"G De Sabbata","year":"2021","unstructured":"De Sabbata G, Boisgerault F, Guarnaccia C, Iaconcig A, Bortolussi G, Collaud F, Ronzitti G, Sola MS, Vidal P, Rouillon J, et al. Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector. Mol Ther Methods Clin Dev. 2021;20:169\u201380.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR325","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.omtm.2019.12.004","volume":"17","author":"DY Richards","year":"2020","unstructured":"Richards DY, Winn SR, Dudley S, Nygaard S, Mighell TL, Grompe M, Harding CO. AAV-Mediated CRISPR\/Cas9 Gene Editing in Murine Phenylketonuria. Mol Ther Methods Clin Dev. 2020;17:234\u201345.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR326","first-page":"1858","volume":"12","author":"D Jerico","year":"2022","unstructured":"Jerico D, Cordoba KM, Sampedro A, Jiang L, Joucla G, Cabanne C, Lanciego JL, Martini PGV, Berraondo P, Avila MA, Fontanellas A. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment. Life (Basel). 2022;12:1858.","journal-title":"Life (Basel)"},{"key":"4518_CR327","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.omtm.2021.06.015","volume":"22","author":"PO Ilyinskii","year":"2021","unstructured":"Ilyinskii PO, Michaud AM, Rizzo GL, Roy CJ, Leung SS, Elkins SL, Capela T, Chowdhury A, Li L, Chandler RJ, et al. ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia. Mol Ther Methods Clin Dev. 2021;22:279\u201392.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR328","doi-asserted-by":"publisher","first-page":"108545","DOI":"10.1016\/j.ymgme.2024.108545","volume":"143","author":"T Higuchi","year":"2024","unstructured":"Higuchi T, Shimada Y, Takahashi Y, Kato F, Ohashi T, Kobayashi H. Restoration of peripheral neuropathy in Fabry mice via intrathecal administration of an adeno-associated virus vector encoding mGLA cDNA. Mol Genet Metab. 2024;143:108545.","journal-title":"Mol Genet Metab"},{"key":"4518_CR329","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","volume":"30","author":"JM Jeyakumar","year":"2023","unstructured":"Jeyakumar JM, Kia A, Tam LCS, McIntosh J, Spiewak J, Mills K, Heywood W, Chisari E, Castaldo N, Verhoef D, et al. Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease. Gene Ther. 2023;30:487\u2013502.","journal-title":"Gene Ther"},{"key":"4518_CR330","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/biomedicines13030577","volume":"13","author":"W Ruangsiriluk","year":"2025","unstructured":"Ruangsiriluk W, Deshpande M, Boukharov N, Rajarshi G, Mukherji S, Yuan S, Wiseman J, Chen N, Park E, Cho H, Islam R. Reversing Pathology in an Aggravated Fabry Mouse Model Using Low-Dose Engineered Human Alpha-Galactosidase A AAV Gene Therapy. Biomedicines. 2025;13:577.","journal-title":"Biomedicines"},{"key":"4518_CR331","doi-asserted-by":"publisher","first-page":"104627","DOI":"10.1016\/j.ebiom.2023.104627","volume":"92","author":"P Kell","year":"2023","unstructured":"Kell P, Sidhu R, Qian M, Mishra S, Nicoli ER, D\u2019Souza P, Tifft CJ, Gross AL, Gray-Edwards HL, Martin DR, et al. A pentasaccharide for monitoring pharmacodynamic response to gene therapy in GM1 gangliosidosis. EBioMedicine. 2023;92:104627.","journal-title":"EBioMedicine"},{"key":"4518_CR332","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1056\/NEJMoa2412392","volume":"392","author":"B Greenberg","year":"2025","unstructured":"Greenberg B, Taylor M, Adler E, Colan S, Ricks D, Yarabe P, Battiprolu P, Shah G, Patel K, Coggins M, et al. Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease. N Engl J Med. 2025;392:972\u201383.","journal-title":"N Engl J Med"},{"key":"4518_CR333","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1056\/NEJMe2414477","volume":"392","author":"EJ Rubin","year":"2025","unstructured":"Rubin EJ, Leopold J, Morrissey S. NEJM at AHA - Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease. N Engl J Med. 2025;392:e27.","journal-title":"N Engl J Med"},{"key":"4518_CR334","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ymgme.2017.01.003","volume":"120","author":"GY Kim","year":"2017","unstructured":"Kim GY, Lee YM, Kwon JH, Cho JH, Pan CJ, Starost MF, Mansfield BC, Chou JY. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-alpha activity restored are at risk of developing hepatic tumors. Mol Genet Metab. 2017;120:229\u201334.","journal-title":"Mol Genet Metab"},{"key":"4518_CR335","doi-asserted-by":"publisher","first-page":"e171281","DOI":"10.1172\/jci.insight.171281","volume":"8","author":"A Padula","year":"2023","unstructured":"Padula A, Spinelli M, Nusco E, Bujanda Cundin X, Capolongo F, Campione S, Perna C, Bastille A, Ericson M, Wang CC, et al. Genome editing without nucleases confers proliferative advantage to edited hepatocytes and corrects Wilson disease. JCI Insight. 2023;8:e171281.","journal-title":"JCI Insight"},{"key":"4518_CR336","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3390\/cells13141214","volume":"13","author":"W Choi","year":"2024","unstructured":"Choi W, Cha S, Kim K. Navigating the CRISPR\/Cas Landscape for Enhanced Diagnosis and Treatment of Wilson\u2019s Disease. Cells. 2024;13:1214.","journal-title":"Cells"},{"key":"4518_CR337","doi-asserted-by":"publisher","first-page":"101363","DOI":"10.1016\/j.omtm.2024.101363","volume":"32","author":"X Shi","year":"2024","unstructured":"Shi X, Bortolussi G, Collaud F, Le Brun PR, Bloemendaal LT, Guerchet N, Rudi de Waart D, Sellier P, Duijst S, Veron P, et al. Repeated dosing of AAV-mediated liver gene therapy in juvenile rat and mouse models of Crigler-Najjar syndrome type I. Mol Ther Methods Clin Dev. 2024;32:101363.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4518_CR338","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ymthe.2019.03.003","volume":"27","author":"A Conway","year":"2019","unstructured":"Conway A, Mendel M, Kim K, McGovern K, Boyko A, Zhang L, Miller JC, DeKelver RC, Paschon DE, Mui BL, et al. Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets. Mol Ther. 2019;27:866\u201377.","journal-title":"Mol Ther"},{"key":"4518_CR339","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/s41551-025-01399-4","volume":"9","author":"T Rothgangl","year":"2025","unstructured":"Rothgangl T, T\u00e1las A, Ioannidi EI, Weber Y, B\u00f6ck D, Matsushita M, Villiger EA, Schmidheini L, Moon WJ, Lin PJC, et al. Treatment of a metabolic liver disease in mice with a transient prime editing approach. Nat Biomedical Eng. 2025;9:1705\u201318.","journal-title":"Nat Biomedical Eng"},{"key":"4518_CR340","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","volume":"12","author":"E Kenjo","year":"2021","unstructured":"Kenjo E, Hozumi H, Makita Y, Iwabuchi KA, Fujimoto N, Matsumoto S, Kimura M, Amano Y, Ifuku M, Naoe Y, et al. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat Commun. 2021;12:7101.","journal-title":"Nat Commun"},{"key":"4518_CR341","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","volume":"163","author":"ME Elder","year":"2013","unstructured":"Elder ME, Nayak S, Collins SW, Lawson LA, Kelley JS, Herzog RW, Modica RF, Lew J, Lawrence RM, Byrne BJ. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2013;163:847\u2013e854841.","journal-title":"J Pediatr"},{"key":"4518_CR342","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymthe.2017.12.008","volume":"26","author":"G Ronzitti","year":"2018","unstructured":"Ronzitti G, Mingozzi F. Combination Therapy Is the New Gene Therapy? Mol Ther. 2018;26:12\u20134.","journal-title":"Mol Ther"},{"key":"4518_CR343","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4161\/auto.24475","volume":"9","author":"DA Thompson","year":"2013","unstructured":"Thompson DA, Klionsky DJ. Autophagy and gene therapy combine in the treatment of liver disease. Autophagy. 2013;9:945\u20136.","journal-title":"Autophagy"},{"key":"4518_CR344","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","volume":"32","author":"B Vrellaku","year":"2024","unstructured":"Vrellaku B, Sethw Hassan I, Howitt R, Webster CP, Harriss E, McBlane F, Betts C, Schettini J, Lion M, Mindur JE, et al. A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders. Mol Ther. 2024;32:3220\u201359.","journal-title":"Mol Ther"},{"key":"4518_CR345","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"MF Yuen","year":"2023","unstructured":"Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN, Lambrecht T, Beumont M, et al. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8:790\u2013802.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4518_CR346","doi-asserted-by":"publisher","first-page":"10264","DOI":"10.3390\/ijms262110264","volume":"26","author":"MT Khan","year":"2025","unstructured":"Khan MT, Al-Dhaleai RE, Alayadhi SM, Alhalwachi Z, Butler AE. The Role of Gene Therapy and RNA-Based Therapeutic Strategies in Diabetes. Int J Mol Sci. 2025;26:10264.","journal-title":"Int J Mol Sci"},{"key":"4518_CR347","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1016\/j.ymthe.2024.09.002","volume":"32","author":"N Sandoval-Villegas","year":"2024","unstructured":"Sandoval-Villegas N, Ivics Z. The best of both worlds: AAV-mediated gene transfer empowered by LNP delivery of Sleeping Beauty transposase for durable transgene expression in vivo. Mol Ther. 2024;32:3211\u20134.","journal-title":"Mol Ther"},{"key":"4518_CR348","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jconrel.2024.07.011","volume":"373","author":"Y Lyu","year":"2024","unstructured":"Lyu Y, Yang X, Yang L, Dai J, Qin H, Zhou Y, Huang Y, Wang Y, Wu D, Shuai Q, et al. Lipid nanoparticle-mediated hepatocyte delivery of siRNA and silibinin in metabolic dysfunction-associated steatotic liver disease. J Control Release. 2024;373:385\u201398.","journal-title":"J Control Release"},{"key":"4518_CR349","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s10020-025-01358-4","volume":"31","author":"DS Kozlov","year":"2025","unstructured":"Kozlov DS, Rodimova S, Filatov P, Mozherov A, Timashev PS, Zyuzin MV, Kuznetsova DS. Genomic medicine in hepatology: mechanisms and liver treatment strategies. Mol Med. 2025;31:302.","journal-title":"Mol Med"},{"key":"4518_CR350","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12951-020-00645-y","volume":"18","author":"D Ji","year":"2020","unstructured":"Ji D, Wang Q, Zhao Q, Tong H, Yu M, Wang M, Lu T, Jiang C. Co-delivery of miR-29b and germacrone based on cyclic RGD-modified nanoparticles for liver fibrosis therapy. J Nanobiotechnol. 2020;18:86.","journal-title":"J Nanobiotechnol"},{"key":"4518_CR351","doi-asserted-by":"publisher","first-page":"e70078","DOI":"10.1002\/jimd.70078","volume":"48","author":"S Gurung","year":"2025","unstructured":"Gurung S, Perocheau D, Ghosh R, Hart SL, Baruteau J. Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases. J Inherit Metab Dis. 2025;48:e70078.","journal-title":"J Inherit Metab Dis"},{"key":"4518_CR352","doi-asserted-by":"publisher","first-page":"e172614","DOI":"10.1172\/jci.insight.172614","volume":"9","author":"L Jauze","year":"2024","unstructured":"Jauze L, Vie M, Miagoux Q, Rossiaud L, Vidal P, Montalvo-Romeral V, Saliba H, Jarrige M, Polveche H, Nozi J, et al. Synergism of dual AAV gene therapy and rapamycin rescues GSDIII phenotype in muscle and liver. JCI Insight. 2024;9:e172614.","journal-title":"JCI Insight"},{"key":"4518_CR353","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41434-019-0098-z","volume":"26","author":"J Serfecz","year":"2019","unstructured":"Serfecz J, Bazick H, Al Salihi MO, Turner P, Fields C, Cruz P, Renne R, Notterpek L. Downregulation of the human peripheral myelin protein 22 gene by miR-29a in cellular models of Charcot-Marie-Tooth disease. Gene Ther. 2019;26:455\u201364.","journal-title":"Gene Ther"},{"key":"4518_CR354","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41541-023-00766-z","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Wang Y, Yuan C, Xu X, Zhou W, Huang Y, Lu H, Zheng Y, Luo G, Shang J, Sui M. Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats. NPJ Vaccines. 2023;8:169.","journal-title":"NPJ Vaccines"},{"key":"4518_CR355","doi-asserted-by":"publisher","first-page":"0017","DOI":"10.34133\/bmr.0017","volume":"28","author":"Y Lee","year":"2024","unstructured":"Lee Y, Jeong M, Lee G, Park J, Jung H, Im S, Lee H. Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics. Biomater Res. 2024;28:0017.","journal-title":"Biomater Res"},{"key":"4518_CR356","doi-asserted-by":"publisher","first-page":"24842","DOI":"10.1021\/acsnano.4c05088","volume":"18","author":"T Korzun","year":"2024","unstructured":"Korzun T, Moses AS, Jozic A, Grigoriev V, Newton S, Kim J, Diba P, Sattler A, Levasseur PR, Le N, et al. Lipid Nanoparticles Elicit Reactogenicity and Sickness Behavior in Mice Via Toll-Like Receptor 4 and Myeloid Differentiation Protein 88 Axis. ACS Nano. 2024;18:24842\u201359.","journal-title":"ACS Nano"},{"key":"4518_CR357","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1038\/mtna.2016.40","volume":"5","author":"T Yanagi","year":"2016","unstructured":"Yanagi T, Tachikawa K, Wilkie-Grantham R, Hishiki A, Nagai K, Toyonaga E, Chivukula P, Matsuzawa S. Lipid Nanoparticle-mediated siRNA Transfer Against PCTAIRE1\/PCTK1\/Cdk16 Inhibits In Vivo Cancer Growth. Mol Ther Nucleic Acids. 2016;5:e327.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4518_CR358","doi-asserted-by":"publisher","first-page":"eadx2681","DOI":"10.1126\/sciadv.adx2681","volume":"11","author":"X Yu","year":"2025","unstructured":"Yu X, Huang C, Evers M, Liu J, Ting HJ, Zhang S, Chong SY, Tan MS, Wang S, Sayed N, et al. Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH. Sci Adv. 2025;11:eadx2681.","journal-title":"Sci Adv"},{"key":"4518_CR359","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/17425247.2025.2452295","volume":"22","author":"A Bak","year":"2025","unstructured":"Bak A, Zhou L, Rejman J, Yanez Arteta M, Nilsson G, Ashford M. Roadmap to discovery and early development of an mRNA loaded LNP formulation for liver therapeutic genome editing. Expert Opin Drug Deliv. 2025;22:239\u201354.","journal-title":"Expert Opin Drug Deliv"},{"key":"4518_CR360","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jhep.2023.02.007","volume":"78","author":"H Luxenburger","year":"2023","unstructured":"Luxenburger H, Reeg DB, Lang-Meli J, Reinscheid M, Eisner M, Bettinger D, Oberhardt V, Salimi Alizei E, Wild K, Graeser A, et al. Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients. J Hepatol. 2023;78:1017\u201327.","journal-title":"J Hepatol"},{"key":"4518_CR361","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1021\/acs.nanolett.2c00275","volume":"22","author":"A Comberlato","year":"2022","unstructured":"Comberlato A, Koga MM, Nussing S, Parish IA, Bastings MMC. Spatially Controlled Activation of Toll-like Receptor 9 with DNA-Based Nanomaterials. Nano Lett. 2022;22:2506\u201313.","journal-title":"Nano Lett"},{"key":"4518_CR362","doi-asserted-by":"publisher","first-page":"eadk9754","DOI":"10.1126\/sciadv.adk9754","volume":"10","author":"X Peng","year":"2024","unstructured":"Peng X, Chen J, Gan Y, Yang L, Luo Y, Bu C, Huang Y, Chen X, Tan J, Yang YY, et al. Biofunctional lipid nanoparticles for precision treatment and prophylaxis of bacterial infections. Sci Adv. 2024;10:eadk9754.","journal-title":"Sci Adv"},{"key":"4518_CR363","doi-asserted-by":"publisher","first-page":"8906","DOI":"10.1038\/s41467-025-63970-6","volume":"16","author":"SP Fuchs","year":"2025","unstructured":"Fuchs SP, Mondragon PG, Zabizhin R, Tomer S, Wang L, Cook E, Dudley DM, Weisgrau KL, Furlott J, Coonen J, et al. Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies. Nat Commun. 2025;16:8906.","journal-title":"Nat Commun"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04518-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04518-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04518-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:02:26Z","timestamp":1783573346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04518-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":363,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4518"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04518-8","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have provided consent for the manuscript to be published in Journal of Nanobiotechnology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"626"}}